

Supporting Information

Table of Contents

| | |
|---|------|
| 1. General experiment information. | S1 |
| Table S1. Optimization of acyloxylation reaction with metal catalysts | S2 |
| Table S2. Optimization of acyloxylation reaction with silver salts | S2 |
| Table S3. Optimization of acyloxylation reaction with other conditions | S3 |
| 2. Preliminary mechanistic studies. | S4 |
| 2.1 Kinetic isotope effect of this transformation | S4 |
| 2.2 The effects of addition of radical scavengers of this reaction | S7 |
| 2.3 Study of intermediate. | S8 |
| 3. Gram-scale experiments | S9 |
| 4. Synthetic transformation | S9 |
| Scheme S1. Pathways to obtain acetamide intermediate | S11 |
| Scheme S2. Failure synthetic strategies to obtain macrocyclic compound. | S11 |
| 5. Single crystal data of product 3aa-8 | S12 |
| 6. Characterization data of silver carboxylates 2a-1-2d-12 | S22 |
| 7. Characterization data of products 3aa-1-3wa | S33 |
| 8. Copies of ¹ H, ¹³ C and ¹⁹ F NMR spectra of silver carboxylates 2a-1-2d-12 | S59 |
| 9. Copies of ¹ H, ¹³ C and ¹⁹ F NMR spectra of products 3aa-1-3wa | S131 |
| 10. Failure examples of C–H bond acyloxylation | S215 |
| 11. References | S216 |

1. General experiment information.


General experimental. Unless otherwise noted, reactions were carried out in single-neck or two-neck flask round bottom flasks, with magnetic stirring. Air- or water-sensitive liquids and solutions were transferred *via* syringe. Organic solutions were concentrated by rotary evaporation at 23–40 °C under 40 Torr (house vacuum). Analytical thin layer chromatography (TLC) was performed with Silicycle normal phase glass plates (0.25 mm, 60-A pore size, 230–400 mesh). Visualization was done under a 254 nm UV light source. Purification of reaction products was generally done by flash chromatography with Silicycle 200–300 mesh silica gel.

Materials. Unless otherwise indicated, all reagents and solvents were purchased for commercial suppliers and used without additional purification. Distilled water was used in the reactions. Picolinamides **1a–1z** and **D-1a** were prepared according to literature procedures.^[S1]

Instrumentation. ¹H NMR, ¹³C NMR and ¹⁹F NMR spectra were recorded on a 400 MHz spectrometer (400 MHz for ¹H; 100 MHz for ¹³C; 376 MHz for ¹⁹F NMR) at room temperature. All chemical shift values are quoted in ppm referenced residual CHCl₃ at 7.26 ppm, Pyridine at 8.72 and DMSO at 2.50 ppm for ¹H NMR; relative to residual CHCl₃ at 77.0 ppm, Pyridine at 123.44 and DMSO at 40.0 ppm for ¹³C unless otherwise noted. HRMS (ion trap) were obtained from mass spectrometer (ESI). Melting points were recorded on an electrothermal digital melting point apparatus and were uncorrected.


The general procedure for silver carboxylates of 2a-1–2d-16: The substrate carboxylic acid **1** (6 mmol) and silver oxide (2 mmol) were added to 25.0 mL round-bottomed flask, followed by addition of 20.0 mL acetonitrile. The mixture was stirred at room temperature for 12 h. This solid was recovered by filtration and washed with 10 mL of cold acetonitrile (stored in dark). Subsequent drying under vacuum led to the desired product **2**.

The general procedure for new compounds of 3aa-1–3wa: The substrate picolinamides **1** (0.2 mmol), substrate silver carboxylates **2** (0.44 mmol) and CoCl₂ (0.02 mmol, 2.6 mg) were added to 5.0 mL round-bottomed flask, followed by addition of 2.0 mL toluene. The mixture was stirred at 110 °C for 12 h. After cooling to room temperature, the reaction mixture was added with 10 mL of water and then extracted by ethyl acetate (10 mL×3), the organic layers were combined, dried with anhydrous Na₂SO₄, and then filtered. The filtrate was concentrated under vacuum, and the resulting residue was purified by column chromatography (Silica Gel: 200–300 mesh) to afford the desired product **3**.


Table S1. Optimization of acyloxylation reaction with metal catalysts^[a]


| Entry | Catalyst (x mol%) | Yield (%) ^[b] | r.r. (%) ^{[b],[c]} |
|----------|---|--------------------------|-----------------------------|
| 1 | none | N.R. | >95% |
| 2 | CuCl ₂ ·2H ₂ O (20) | N.R. | >95% |
| 3 | PdCl ₂ (20) | N.R. | >95% |
| 4 | CuI (20) | N.R. | 70% |
| 5 | NiCl ₂ (20) | N.R. | >95% |
| 6 | [Rh(COD)Cl] ₂ (20) | N.R. | 70% |
| 7 | [Ir(COD)Cl] ₂ (20) | N.R. | 60% |
| 8 | Co(acac) ₃ (20) | N.R. | 90% |
| 9 | Co(OAc)₂ (20) | 90% | 8% |

^[a] The reaction was carried out with picolinamide **1a** (0.2 mmol, 49.6 mg), **catalyst** (20 mol%) and AgOAc (0.4 mmol, 56.6mg) in 2.0 mL of toluene at 100 °C for 24 h. ^[b] Determined by ¹H-NMR. ^[c] r.r. = Recovery rate.


Table S2. Optimization of acyloxylation reaction with silver salts^[a]


| Entry | CoX ₂ | AgX | Yield (%) ^[b] | r.r. (%) ^{[b],[c]} |
|------------------|----------------------|--------------------|--------------------------|-----------------------------|
| 1 | CoCl ₂ | AgF | N.R. | >95% |
| 2 | CoCl ₂ | AgCl | N.R. | 90% |
| 3 | CoBr ₂ | AgBr | N.R. | >95% |
| 4 | CoI ₂ | AgI | N.R. | 90% |
| 5 | Co(OAc) ₂ | AgOAc | 90 | <5% |
| 6 ^[d] | CoCl ₂ | AgOTfa | N.R. | >95% |
| 7 ^[d] | CoCl ₂ | AgOTf | N.R. | >95% |
| 8 | CoCl ₂ | AgSCN | N.R. | >95% |
| 9 | CoCl ₂ | AgSeCN | N.R. | >95% |
| 10 | CoCl ₂ | AgOCN | N.R. | >95% |
| 11 | CoCl ₂ | AgOMs | N.R. | 90% |
| 12 | CoCl ₂ | AgOTs | N.R. | 90% |
| 13 | CoCl ₂ | Tol-SOOAg | N.R. | 95% |
| 15 | CoCl ₂ | AgNBn ₂ | N.R. | >95% |

| | | | | |
|----|-------------------|---|------|------|
| 20 | CoCl ₂ | CH ₃ COSAg | N.R. | >95% |
| 21 | CoCl ₂ |  | N.R. | >95% |
| 22 | CoCl ₂ | AgNTf ₂ | N.R. | >95% |
| 23 | CoCl ₂ | AgBF ₄ | N.R. | >95% |
| 24 | CoCl ₂ | Ag ₂ WO ₃ | N.R. | >95% |

^[a]The reaction was carried out with picolinamide **1a** (0.2 mmol, 49.6 mg), Co catalyst (20 mol%) and AgX (0.4 mmol, 2.0 eq) in 2.0 mL of toluene at 100 °C for 24 h. ^[b]Determined by ¹H-NMR. ^[c]r.r. = Recovery rate. ^[d]Quenched with water before ¹H-NMR analysis.

Table S3. Optimization of acyloxylation reaction with other conditions^[a]



| Entry | CoX ₂ (x mol%) | AgOAc (x eq.) | solvent | additive (x eq.) | Yield (%) ^[b] |
|-------------------|----------------------------|---------------|-------------|---------------------------------------|--------------------------|
| 1 | Co(OAc) ₂ (20) | 2.0 | DMSO | - | 9% |
| 2 | Co(OAc) ₂ (20) | 2.0 | DME | - | 82% |
| 3 | Co(OAc) ₂ (20) | 2.0 | 1,4-dioxane | - | 58% |
| 4 | Co(OAc) ₂ (20) | 2.0 | 18-crown-6 | - | 20% |
| 5 | Co(OAc) ₂ (20) | 2.0 | toluene | - | 90% |
| 6 | Co(OAc) ₂ (20) | 2.0 | toluene | Cs ₂ CO ₃ (2.0) | 2% |
| 7 | Co(OAc) ₂ (20) | 2.0 | toluene | KOAc (2.0) | 50% |
| 8 | Co(OAc) ₂ (20) | 2.0 | toluene | DMAP (2.0) | N.R. |
| 9 | Co(OAc) ₂ (20) | 2.0 | toluene | H ₂ O (5.0) | 29% |
| 10 ^[c] | Co(OAc) ₂ (20) | 2.0 | toluene | - | 91% |
| 11 ^[d] | Co(OAc) ₂ (20) | 2.0 | toluene | - | 88% |
| 12 ^[e] | Co(OAc) ₂ (20) | 2.0 | toluene | - | 87% |
| 13 | CoF ₂ (20) | 2.0 | toluene | - | 3% |
| 14 | CoCl ₂ (20) | 2.0 | toluene | - | 91% |
| 15 | CoBr ₂ (20) | 2.0 | toluene | - | 71% |
| 16 | CoI ₂ (20) | 2.0 | toluene | - | 74% |
| 17 | CoCO ₃ (20) | 2.0 | toluene | - | <1% |
| 18 | Co(SCN) ₂ (20) | 2.0 | toluene | - | 67% |
| 19 | CoSO ₄ (20) | 2.0 | toluene | - | 8% |
| 20 | Co(acac) ₃ (20) | 2.0 | toluene | - | N.R. |
| 21 ^[f] | CoCl ₂ (1) | 2.0 | toluene | - | 12% |
| 22 ^[f] | CoCl ₂ (5) | 2.0 | toluene | - | 32% |
| 23 ^[f] | CoCl ₂ (10) | 2.0 | toluene | - | 83% |


| | | | | | |
|-----------------------|------------------------|-----|---------|---|-----|
| 24 | CoCl ₂ (10) | 2.0 | toluene | - | 60% |
| 25 | CoCl ₂ (10) | 0.6 | toluene | - | 23% |
| 26 | CoCl ₂ (10) | 1.0 | toluene | - | 43% |
| 27 | CoCl ₂ (10) | 2.2 | toluene | - | 82% |
| 28 ^{[g],[h]} | CoCl ₂ (10) | 2.2 | toluene | - | 92% |

^[a]Unless other notes, the reaction was carried out with picolinamide **1a** (0.2 mmol, 49.6 mg), Co catalyst (20 mmol%) and AgOAc (0.4 mmol, 66.8 mg, 2.0 eq) in 2.0 mL of solvent at 100 °C for 24 h.

^[b]Determined by ¹H-NMR. ^[c]Under O₂ atmosphere. ^[d]Under N₂ atmosphere. ^[e]Aged Co(OAc)₂. ^[f]For 48 h. ^[g]For 12 h. ^[h]At 110 °C.

2. Preliminary mechanistic studies.

2.1 Kinetic isotope effect (KIE) of the transformation



The picolinamides (**2a**, 0.2 mmol, 49.6 mg or **D-2a**, 0.2 mmol, 49.8 mg), AgOAc (**2a-1**, 0.44 mmol, 73.5 mg) and CoCl₂ (0.02 mmol, 2.6 mg) were added to 5.0 mL round-bottomed flask, followed by addition of 2.0 mL xylene as solvent. The mixture was stirred at 110 °C. An aliquot of each reaction mixture was taken at 1 h, 2 h, 3 h and 4 h. After the solvent of each aliquot (0.5 mL) was removed under reduced pressure conditions and analyzed by ¹H NMR spectrum in CDCl₃ (see Figure S1 and Figure S2). The relative yield of **1a** and **D-1a** were shown in Table S4. A sample plot of the initial rate data for the reaction of both **1a** and **D-1a** was shown in Figure S3 and Figure S4. The reaction progress in the early stage (0-4 h) indicated a kinetic isotope effect (KIE) of 1.46.




Figure S1. The conversion of **1a** was monitored by ¹H NMR method




Figure S2. The conversion of **D-1a** was monitored by ¹H NMR method

Table S4. The relative yields (%) of 3aa-1 was monitored by ¹H NMR method.

| Time [h] | 1 | 2 | 3 | 4 |
|---|------|-------|-------|-------|
| ¹ H NMR yield of 3aa from 2a [%] | 2.22 | 11.42 | 31.15 | 54.95 |
| ¹ H NMR yield of 3aa from D-2a [%] | 1.78 | 10.48 | 21.41 | 38.76 |




Figure S3. The plot of initial rates for the conversion of **1a**






Figure S4. The plot of initial rates for the conversion of **D-1a**


2.2 The effects of addition of radical scavengers of the reaction.



The picolinamides **1a** (0.2 mmol, 49.6 mg), CoCl₂ (0.02 mmol, 2.6 mg), AgOAc (0.44 mmol, 73.5 mg) and **TEMPO** (0.4 mmol, 62.5 mg, 2.0 eq.) were added to 5.0 mL round-bottomed flask, followed by addition of 2.0 mL toluene as solvent. The mixture was stirred at 110 °C for 12 h. After cooling to room temperature, the reaction mixture was added with 10 mL of water and then extracted by ethyl acetate (10 mL×3), the organic layers were combined, dried with anhydrous Na₂SO₄, and then filtered. The filtrate was concentrated under vacuum, and the yield of **3aa-1** was determined by ¹H-NMR in CDCl₃. (The result indicated that radical process should not involve in the acyloxylation reaction.)




The picolinamides **1a** (0.2 mmol, 49.6 mg), CoCl₂ (0.02 mmol, 2.6 mg), AgOAc (0.44 mmol, 73.5 mg) and **BHT** were added to 5.0 mL round-bottomed flask, followed by addition of 2.0 mL toluene as solvent. The mixture was stirred at 110 °C for 12 h. After cooling to room temperature, the reaction mixture was added with 10 mL of water and then extracted by ethyl acetate (10 mL×3), the organic layers were combined, dried with anhydrous Na₂SO₄, and then filtered. The filtrate was concentrated under vacuum, and the yields of **3da** with different loading amount of BTH was determined by ¹H-NMR in CDCl₃. (The result indicated that radical process should not involve in the acyloxylation reaction. BHT might be oxidized by AgOAc.)




In order to figure out the relationship/reaction between AgOAc and BHT, the following reaction was carried out: AgOAc (0.2 mmol, 53.4 mg) and BHT (0.2 mmol, 44.0 mg) were added to 5.0 mL round-bottomed flask, followed by addition of 2.0 mL toluene as solvent. The mixture was stirred at 110 °C for 12 h. After cooling to room temperature, the reaction mixture was filtered. The filtrate was concentrated under vacuum. A crude ¹H-NMR analysis in CDCl₃ was tested without further purification. (The result of the ¹H-NMR analysis indicated that BHT could be oxidized by AgOAc. The oxidation reaction is similar to the reaction between BHT and Ag₂O in hexane reported by Prof. Richard Cosstick.^[S2])

2.3 Study of intermediate.




The picolinamides **1a** (0.5 mmol, 124.0 mg) and Co(OAc)₂ (0.5 mmol, 88.5 mg) were added to 25.0 mL round-bottomed flask, followed by addition of 5.0 mL CF₃CH₂OH as solvent. The mixture was stirred at 70 °C for 12 h under O₂ atmosphere. After cooling to room temperature, the reaction mixture was concentrated under vacuum to remove CF₃CH₂OH, and the resulting residue was purified by column chromatography (PE:EA=1:1, then 100% of EA) to afford the intermediate **Co-1d**.^[S3]




The intermediate **Co-1d** (0.02 mmol, 7.6 mg), picolinamides **1d** (0.18 mmol, 47.2 mg) and AgOAc (0.4 mmol, 66.8 mg) were added to 25.0 mL round-bottomed flask, followed by addition of 5.0 mL toluene as solvent. The mixture was stirred at 110 °C for **6 h**. After cooling to room temperature, the reaction mixture was added with 10 mL of water and then extracted by ethyl acetate (10 mL×3), the organic layers were combined, dried with anhydrous Na₂SO₄, and then filtered. The filtrate was concentrated under vacuum, and the resulting residue was purified by column chromatography to afford the desired product **3da** in 42% yield (vs the 73% yield under the optimized condition for **12 h**). (The result indicated that complex **Co-1d** should be the key intermediate for the further acyloxylation reaction to form product **3da**.)

3. Gram-scale experiments




The picolinamides **1a** (0.5 mmol, 1.984 g), CoCl₂ (0.8 mmol, 0.104 g) and AgOAc (17.6 mmol, 2.939 g) were added to 100.0 mL round-bottomed flask, followed by addition of 50.0 mL toluene as solvent. The mixture was stirred at 110 °C for 12 h. After cooling to room temperature, the reaction mixture was added with 100 mL of water and then extracted by ethyl acetate (50 mL×3), the organic layers were combined, dried with anhydrous Na₂SO₄, and then filtered. The filtrate was concentrated under vacuum, and the resulting residue was purified by column chromatography to afford the desired product **3aa-1** in 80% yield.

4. Synthetic transformation.




3aa-1 (61.2 mg, 0.2 mmol, 1.0 equiv.), Cu(OAc)₂ (8.0 mg, 0.04 mmol, 0.2 equiv.), PhI(OAc)₂ (128.8 mg, 0.4 mmol, 2.0 equiv.) and CH₃COOH (2 mL) were successively added into a sealed tube. The mixture was stirred at 80 °C under air for 12 h. After cooling to ambient temperature, the resulting mixture was filtered through a pad of tripolite and washed with ethyl acetate. The filtrate was concentrated under vacuum and purified by column chromatography (Silica Gel: 200–300 mesh) to afford the desired product **4**.




3aa-1 (61.2 mg, 0.2 mmol, 1.0 equiv.), Cu(OAc)₂ (8.0 mg, 0.04 mmol, 0.2 equiv.), TBHP (5.5 mol / L in decane, 0.2 mmol, 1.0 equiv.), CF₃SO₂Na (93.6 mg, 0.6 mmol, 3.0 equiv.), and CH₃CN (2 mL) were successively added into a sealed tube. The mixture was stirred at 80 °C under air for 48 h. After cooling to ambient temperature, the resulting mixture was filtered through a pad of tripolite and washed


with ethyl acetate. The filtrate was concentrated under vacuum and purified by column chromatography (Silica Gel: 200–300 mesh) to afford the desired product **5**.




3aa-1 (61.2 mg, 0.2 mmol, 1.0 equiv.), Cu(OAc)₂ (8.0 mg, 0.04 mmol, 0.2 equiv.), Mn(OAc)₃ (185.6 mg, 0.8 mmol, 4.0 equiv.), NaOAc (49.2 mg, 0.6 mmol, 3.0 equiv.), TsNa (142.4 mg, 0.8 mmol, 4.0 equiv.), and HFIP (2 mL) were added into a sealed tube. The mixture was stirred at 60 °C for 2 h. After cooling to ambient temperature, the resulting mixture was filtered through a pad of tripolite and washed with ethyl acetate. The filtrate was concentrated under vacuum and purified by column chromatography (Silica Gel: 200–300 mesh) to afford the desired product **6**.




3aa-1 (61.2 mg, 0.2 mmol, 1.0 equiv.), NaOH (16.0 mg, 0.4 mmol, 2.0 equiv.), and solvent (THF/MeOH/H₂O, v:v:v=2:1:1, 2 mL) were successively added into a sealed tube. The mixture was stirred at room temperature for 12 h. The reaction mixture was added with 10 mL of H₂O and then extracted by DCM (10 mL×3), the organic layers were combined, dried with anhydrous Na₂SO₄, and then filtered. The filtrate was concentrated under vacuum, and the resulting residue was purified by column chromatography to afford the desired product **7**.



3aa-1 (61.2 mg, 0.2 mmol, 1.0 equiv.), NaOH (64.0 mg, 1.6 mmol, 8.0 equiv.), and solvent (THF/EtOH/H₂O, v:v:v=2:1:1, 2 mL) were successively added into a sealed tube. The mixture was stirred at 100 °C for 48 h under N₂ atmosphere. The reaction mixture was added with 10 mL of H₂O and then extracted by ethyl acetate (10 mL×3), the organic layers were combined, dried with anhydrous Na₂SO₄, and then filtered. The filtrate was concentrated under vacuum, and the resulting residue was purified by column chromatography to afford the desired product **8**.



Scheme S1. Pathways to obtain acetamide intermediate **8**



Scheme S2. Failure synthetic strategies to obtain macrocyclic compound

5. Single crystal data of product **3aa-8** (CCDC 2160352)




Figure S5. The single crystal structure of **3aa**

Table S3. Crystal data and structure refinement for **3aa-8**

| | |
|---|---|
| Identification code | 0912CHACC3_0m (3aa-8) |
| Empirical formula | C ₂₀ H ₁₆ N ₂ O ₃ |
| Formula weight | 332.35 |
| Temperature | 150 K |
| Wavelength | 0.71073 Å |
| Space group Crystal system | triclinic |
| Space group IT number | 2 |
| Space group name H-M alt | P -1 |
| Unit cell dimensions | a = 10.6196(8) Å alpha = 75.187(2) deg. b = 12.7360(9) Å beta = 70.684(2) deg. c = 13.6446(9) Å gamma = 69.536(2) deg. |
| Volume | 1611.1(2) Å ³ |
| Z, Calculated density | 4, 1.370 Mg/m ³ |
| Absorption coefficient | 0.094 mm ⁻¹ |
| F(000) | 696 |
| Crystal size | 0.15 x 0.08 x 0.05 mm |
| Theta range for data collection | 2.124 to 26.436 deg. |
| Limiting indices | -13<=h<=13, -15<=k<=15, -17<=l<=14 |
| Reflections collected | 4253 |
| Completeness to theta = 25.242 | 99.7% |
| Absorption correction | SADABS-2016/2 (Bruker,2016/2) |
| The ratio of min. to max. transmission | 0.8704 |
| Refinement method | none |
| Data / restraints / parameters | 6559 / 0 / 451 |
| Goodness-of-fit on F ² | 1.048 |
| Final R indices [F _o >4sigma(F _o)] | R1 = 0.0532 |
| R indices (all data) | R1 = 0.0991, wR2 = 0.1295 |
| Absolute structure parameter | n/a |
| Largest diff. peak and hole | 0.21 and -0.26 e.Å ⁻³ |

Table S4. Atomic coordinates ($\times 10^4$) and equivalent isotropic displacement parameters ($\text{\AA}^2 \times 10^3$) for **3aa-8**

| Atom | x/a | y/b | z/c | U/eq |
|------|-----------|-----------|-----------|-----------|
| O6 | 0.9303(2) | 1.0408(1) | 0.8505(1) | 0.0453(5) |
| O5 | 0.7635(2) | 0.9509(1) | 0.9163(1) | 0.0279(4) |
| O4 | 0.5028(2) | 1.2659(1) | 0.7073(1) | 0.0357(4) |
| O3 | 0.5618(2) | 0.7053(1) | 0.6329(1) | 0.0406(4) |
| O2 | 0.7443(2) | 0.5550(1) | 0.5824(1) | 0.0282(4) |
| O1 | 1.0380(2) | 0.5891(2) | 0.7826(1) | 0.0500(5) |
| N4 | 0.5673(2) | 1.1096(2) | 0.8276(1) | 0.0274(4) |
| N3 | 0.6761(2) | 0.9781(2) | 0.6807(1) | 0.0300(4) |
| N2 | 0.8121(2) | 0.4237(2) | 0.8281(1) | 0.0340(5) |
| N1 | 0.9361(2) | 0.5601(2) | 0.6710(1) | 0.0281(4) |
| H9 | 1.24650 | 0.73480 | 0.45410 | 0.0440 |
| H8 | 1.14890 | 0.63650 | 0.61540 | 0.0390 |
| H5 | 0.69610 | 0.31920 | 0.88800 | 0.0510 |
| H4A | 0.61160 | 1.03650 | 0.83320 | 0.0330 |
| H40B | 1.14390 | 0.76480 | 0.72500 | 0.0460 |
| H40A | 1.15520 | 0.87100 | 0.76910 | 0.0460 |
| H4 | 0.78200 | 0.22880 | 1.03300 | 0.0540 |
| H39B | 1.03440 | 1.00530 | 0.64770 | 0.0500 |
| H39A | 1.02310 | 0.89910 | 0.60370 | 0.0500 |
| H38 | 0.89170 | 0.83510 | 0.77720 | 0.0350 |
| H36 | 0.55160 | 1.14290 | 1.24470 | 0.0370 |
| H35 | 0.74380 | 0.98560 | 1.23490 | 0.0400 |
| H34 | 0.84220 | 0.90160 | 1.08110 | 0.0370 |
| H30 | 0.37150 | 1.28510 | 1.16920 | 0.0400 |
| H3 | 0.95060 | 0.28740 | 1.06310 | 0.0520 |
| H29 | 0.26980 | 1.36390 | 1.03180 | 0.0440 |
| H28 | 0.35980 | 1.28430 | 0.87720 | 0.0390 |
| H24 | 0.54020 | 1.20470 | 0.53270 | 0.0350 |
| H23 | 0.62070 | 1.07740 | 0.41230 | 0.0390 |
| H22 | 0.73560 | 0.88750 | 0.46350 | 0.0400 |
| H21 | 0.77080 | 0.83090 | 0.63010 | 0.0420 |
| H20B | 0.35920 | 0.47830 | 0.73550 | 0.0650 |
| H20A | 0.34700 | 0.61490 | 0.68860 | 0.0650 |
| H2 | 1.03340 | 0.43200 | 0.94000 | 0.0430 |
| H19B | 0.42710 | 0.62630 | 0.82790 | 0.0660 |
| H19A | 0.43930 | 0.48970 | 0.87480 | 0.0660 |
| H18 | 0.60750 | 0.43690 | 0.71280 | 0.0400 |
| H15 | 0.67020 | 0.63250 | 0.41500 | 0.0360 |

| | | | | |
|-----|-----------|-----------|-----------|-----------|
| H14 | 0.76650 | 0.74180 | 0.25960 | 0.0410 |
| H13 | 0.95990 | 0.79300 | 0.24650 | 0.0390 |
| H10 | 1.14400 | 0.78730 | 0.31800 | 0.0410 |
| H1 | 0.87500 | 0.52800 | 0.67100 | 0.0340 |
| C9 | 1.1644(3) | 0.7154(2) | 0.4630(2) | 0.0364(6) |
| C8 | 1.1063(2) | 0.6556(2) | 0.5595(2) | 0.0326(5) |
| C7 | 0.9892(2) | 0.6242(2) | 0.5747(2) | 0.0267(5) |
| C6 | 0.9679(2) | 0.5421(2) | 0.7635(2) | 0.0312(5) |
| C5 | 0.7665(3) | 0.3418(2) | 0.8984(2) | 0.0425(6) |
| C40 | 1.1019(2) | 0.8442(2) | 0.7383(2) | 0.0385(6) |
| C4 | 0.8161(3) | 0.2880(2) | 0.9858(2) | 0.0448(7) |
| C39 | 1.0274(3) | 0.9269(2) | 0.6636(2) | 0.0416(6) |
| C38 | 0.9450(2) | 0.8883(2) | 0.7716(2) | 0.0291(5) |
| C37 | 0.8843(2) | 0.9687(2) | 0.8467(2) | 0.0296(5) |
| C36 | 0.5900(2) | 1.1090(2) | 1.1828(2) | 0.0310(5) |
| C35 | 0.7039(3) | 1.0164(2) | 1.1771(2) | 0.0331(5) |
| C34 | 0.7624(2) | 0.9661(2) | 1.0855(2) | 0.0312(5) |
| C33 | 0.7044(2) | 1.0100(2) | 1.0029(2) | 0.0262(5) |
| C32 | 0.5850(2) | 1.1059(2) | 1.0040(2) | 0.0246(5) |
| C31 | 0.5278(2) | 1.1558(2) | 1.0984(2) | 0.0282(5) |
| C30 | 0.4092(2) | 1.2524(2) | 1.1066(2) | 0.0333(5) |
| C3 | 0.9159(3) | 0.3217(2) | 1.0030(2) | 0.0435(6) |
| C29 | 0.3490(3) | 1.2988(2) | 1.0256(2) | 0.0365(6) |
| C28 | 0.4033(2) | 1.2510(2) | 0.9329(2) | 0.0329(5) |
| C27 | 0.5176(2) | 1.1576(2) | 0.9209(2) | 0.0265(5) |
| C26 | 0.5540(2) | 1.1639(2) | 0.7305(2) | 0.0257(5) |
| C25 | 0.6088(2) | 1.0863(2) | 0.6504(2) | 0.0244(5) |
| C24 | 0.5870(2) | 1.1270(2) | 0.5516(2) | 0.0293(5) |
| C23 | 0.6348(2) | 1.0521(2) | 0.4807(2) | 0.0329(5) |
| C22 | 0.7026(2) | 0.9408(2) | 0.5105(2) | 0.0337(6) |
| C21 | 0.7221(2) | 0.9078(2) | 0.6104(2) | 0.0346(6) |
| C20 | 0.3951(3) | 0.5430(2) | 0.7270(3) | 0.0545(8) |
| C2 | 0.9644(3) | 0.4068(2) | 0.9308(2) | 0.0357(6) |
| C19 | 0.4445(3) | 0.5499(2) | 0.8124(2) | 0.0547(8) |
| C18 | 0.5495(2) | 0.5180(2) | 0.7121(2) | 0.0334(5) |
| C17 | 0.6131(2) | 0.6043(2) | 0.6417(2) | 0.0286(5) |
| C16 | 0.8040(2) | 0.6249(2) | 0.4936(2) | 0.0266(5) |
| C15 | 0.7486(2) | 0.6551(2) | 0.4101(2) | 0.0299(5) |
| C14 | 0.8068(2) | 0.7192(2) | 0.3171(2) | 0.0338(5) |
| C13 | 0.9212(2) | 0.7491(2) | 0.3096(2) | 0.0324(5) |
| C12 | 0.9235(2) | 0.6529(2) | 0.4911(2) | 0.0265(5) |
| C11 | 0.9836(2) | 0.7159(2) | 0.3940(2) | 0.0291(5) |

| | | | | |
|-----|-----------|-----------|-----------|-----------|
| C10 | 1.1046(2) | 0.7458(2) | 0.3825(2) | 0.0338(6) |
| C1 | 0.9102(2) | 0.4541(2) | 0.8452(2) | 0.0285(5) |

Table S5. Bond lengths [Å] and angles [deg] for **3aa-8**

| | |
|---------|----------|
| O2-C17 | 1.375(3) |
| O2-C16 | 1.413(2) |
| O5-C33 | 1.410(2) |
| O5-C37 | 1.374(3) |
| O4-C26 | 1.222(2) |
| O3-C17 | 1.201(3) |
| O6-C37 | 1.200(3) |
| O1-C6 | 1.225(3) |
| N1-H1 | 0.8800 |
| N1-C7 | 1.412(3) |
| N1-C6 | 1.355(3) |
| N4-H4A | 0.8800 |
| N4-C26 | 1.357(3) |
| N4-C27 | 1.414(3) |
| N3-C25 | 1.341(3) |
| N3-C21 | 1.336(3) |
| N2-C1 | 1.335(3) |
| N2-C5 | 1.333(3) |
| C33-C32 | 1.419(3) |
| C33-C34 | 1.363(3) |
| C26-C25 | 1.496(3) |
| C25-C24 | 1.381(3) |
| C32-C27 | 1.435(3) |
| C32-C31 | 1.436(3) |
| C11-C12 | 1.435(3) |
| C11-C13 | 1.416(3) |
| C11-C10 | 1.413(3) |
| C12-C7 | 1.435(3) |
| C12-C16 | 1.421(3) |
| C7-C8 | 1.373(3) |
| C17-C18 | 1.462(3) |
| C1-C6 | 1.505(3) |
| C1-C2 | 1.377(3) |
| C37-C38 | 1.467(3) |
| C27-C28 | 1.369(3) |
| C15-H15 | 0.9500 |
| C15-C16 | 1.361(3) |
| C15-C14 | 1.401(3) |

| | |
|----------|----------|
| C31-C36 | 1.413(3) |
| C31-C30 | 1.417(3) |
| C8-H8 | 0.9500 |
| C8-C9 | 1.405(3) |
| C24-H24 | 0.9500 |
| C24-C23 | 1.383(3) |
| C13-H13 | 0.9500 |
| C13-C14 | 1.361(3) |
| C34-H34 | 0.9500 |
| C34-C35 | 1.406(3) |
| C35-H35 | 0.9500 |
| C35-C36 | 1.359(3) |
| C38-H38 | 1.0000 |
| C38-C40 | 1.508(3) |
| C38-C39 | 1.502(3) |
| C23-H23 | 0.9500 |
| C23-C22 | 1.370(3) |
| C14-H14 | 0.9500 |
| C10-H10 | 0.9500 |
| C10-C9 | 1.353(3) |
| C28-H28 | 0.9500 |
| C28-C29 | 1.403(3) |
| C36-H36 | 0.9500 |
| C22-H22 | 0.9500 |
| C22-C21 | 1.382(3) |
| C2-H2 | 0.9500 |
| C2-C3 | 1.386(3) |
| C30-H30 | 0.9500 |
| C30-C29 | 1.360(3) |
| C18-H18 | 1.0000 |
| C18-C20 | 1.509(3) |
| C18-C19 | 1.496(3) |
| C21-H21 | 0.9500 |
| C29-H29 | 0.9500 |
| C9-H9 | 0.9500 |
| C40-H40A | 0.9900 |
| C40-H40B | 0.9900 |
| C40-C39 | 1.475(3) |
| C39-H39A | 0.9900 |
| C39-H39B | 0.9900 |
| C3-H3 | 0.9500 |
| C3-C4 | 1.377(4) |

| | |
|-------------|------------|
| C5-H5 | 0.9500 |
| C5-C4 | 1.384(3) |
| C4-H4 | 0.9500 |
| C20-H20A | 0.9900 |
| C20-H20B | 0.9900 |
| C20-C19 | 1.459(4) |
| C19-H19A | 0.9900 |
| C19-H19B | 0.9900 |
| C17-O2-C16 | 116.98(16) |
| C37-O5-C33 | 117.10(15) |
| C7-N1-H1 | 116.100 |
| C6-N1-H1 | 116.100 |
| C6-N1-C7 | 127.88(18) |
| C26-N4-H4A | 116.500 |
| C26-N4-C27 | 127.07(19) |
| C27-N4-H4A | 116.500 |
| C21-N3-C25 | 116.93(19) |
| C5-N2-C1 | 116.9(2) |
| O5-C33-C32 | 120.13(18) |
| C34-C33-O5 | 116.7(2) |
| C34-C33-C32 | 123.0(2) |
| O4-C26-N4 | 125.2(2) |
| O4-C26-C25 | 121.29(19) |
| N4-C26-C25 | 113.49(19) |
| N3-C25-C26 | 116.73(19) |
| N3-C25-C24 | 123.3(2) |
| C24-C25-C26 | 120.0(2) |
| C33-C32-C27 | 126.74(19) |
| C33-C32-C31 | 115.78(19) |
| C27-C32-C31 | 117.5(2) |
| C13-C11-C12 | 120.1(2) |
| C10-C11-C12 | 120.2(2) |
| C10-C11-C13 | 119.7(2) |
| C7 C12-C11 | 117.54(19) |
| C16 C12-C11 | 115.75(19) |
| C16 C12-C7 | 126.71(19) |
| N1-C7-C12 | 119.83(18) |
| C8-C7-N1 | 120.3(2) |
| C8-C7-C12 | 119.9(2) |
| O2-C17-C18 | 110.97(18) |
| O3-C17-O2 | 122.2(2) |
| O3-C17-C18 | 126.8(2) |

| | |
|-------------|------------|
| N2-C1-C6 | 117.3(2) |
| N2-C1-C2 | 123.8(2) |
| C2-C1-C6 | 118.8(2) |
| O5-C37-C38 | 110.67(18) |
| O6-C37-O5 | 122.5(2) |
| O6-C37-C38 | 126.8(2) |
| N4-C27-C32 | 119.63(19) |
| C28-C27-N4 | 120.1(2) |
| C28-C27-C32 | 120.2(2) |
| C16-C15-H15 | 119.800 |
| C16-C15-C14 | 120.3(2) |
| C14-C15-H15 | 119.800 |
| C36-C31-C32 | 120.1(2) |
| C36-C31-C30 | 120.0(2) |
| C30-C31-C32 | 119.9(2) |
| O2-C16-C12 | 120.00(19) |
| C15-C16-O2 | 116.85(19) |
| C15-C16-C12 | 122.95(19) |
| C7-C8-H8 | 119.300 |
| C7-C8-C9 | 121.4(2) |
| C9-C8-H8 | 119.300 |
| C25-C24-H24 | 120.800 |
| C25-C24-C23 | 118.5(2) |
| C23-C24-H24 | 120.800 |
| C11-C13-H13 | 119.400 |
| C14-C13-C11 | 121.2(2) |
| C14-C13-H13 | 119.400 |
| O1-C6-N1 | 125.8(2) |
| O1-C6-C1 | 120.5(2) |
| N1-C6-C1 | 113.64(19) |
| C33-C34-H34 | 120.000 |
| C33-C34-C35 | 120.0(2) |
| C35-C34-H34 | 120.000 |
| C34-C35-H35 | 120.100 |
| C36-C35-C34 | 119.8(2) |
| C36-C35-H35 | 120.100 |
| C37-C38-H38 | 117.000 |
| C37-C38-C40 | 116.79(19) |
| C37-C38-C39 | 117.44(19) |
| C40-C38-H38 | 117.000 |
| C39-C38-H38 | 117.000 |
| C39-C38-C40 | 58.70(15) |

| | |
|---------------|-----------|
| C24-C23-H23 | 120.400 |
| C22-C23-C24 | 119.1(2) |
| C22-C23-H23 | 120.400 |
| C15-C14-H14 | 120.200 |
| C13-C14-C15 | 119.7(2) |
| C13-C14-H14 | 120.200 |
| C11-C10-H10 | 119.900 |
| C9-C10-C11 | 120.3(2) |
| C9-C10-H10 | 119.900 |
| C27-C28-H28 | 119.200 |
| C27-C28-C29 | 121.5(2) |
| C29-C28-H28 | 119.200 |
| C31-C36-H36 | 119.400 |
| C35-C36-C31 | 121.2(2) |
| C35-C36-H36 | 119.400 |
| C23-C22-H22 | 120.700 |
| C23-C22-C21 | 118.6(2) |
| C21-C22-H22 | 120.700 |
| C1-C2-H2 | 120.700 |
| C1-C2-C3 | 118.5(2) |
| C3-C2-H2 | 120.700 |
| C31-C30-H30 | 119.700 |
| C29-C30-C31 | 120.6(2) |
| C29-C30-H30 | 119.700 |
| C17-C18-H18 | 117.400 |
| C17-C18-C20 | 115.9(2) |
| C17-C18-C19 | 117.5(2) |
| C20-C18-H18 | 117.400 |
| C19-C18-H18 | 117.400 |
| C19-C18-C20 | 58.07(18) |
| N3-C21-C22 | 123.6(2) |
| N3-C21-H21 | 118.200 |
| C22-C21-H21 | 118.200 |
| C28-C29-H29 | 119.900 |
| C30-C29-C28 | 120.3(2) |
| C30-C29-H29 | 119.900 |
| C8-C9-H9 | 119.600 |
| C10-C9-C8 | 120.7(2) |
| C10-C9-H9 | 119.600 |
| C38-C40-H40A | 117.700 |
| C38-C40-H40B | 117.700 |
| H40A-C40-H40B | 114.800 |


| | |
|---------------|-----------|
| C39-C40-C38 | 60.45(15) |
| C39-C40-H40A | 117.700 |
| C39-C40-H40B | 117.700 |
| C38-C39-H39A | 117.700 |
| C38-C39-H39B | 117.700 |
| C40-C39-C38 | 60.84(15) |
| C40-C39-H39A | 117.700 |
| C40-C39-H39B | 117.700 |
| H39A-C39-H39B | 114.800 |
| C2-C3-H3 | 120.800 |
| C4-C3-C2 | 118.4(2) |
| C4-C3-H3 | 120.800 |
| N2-C5-H5 | 118.300 |
| N2-C5-C4 | 123.5(2) |
| C4-C5-H5 | 118.300 |
| C3-C4-C5 | 118.8(2) |
| C3-C4-H4 | 120.600 |
| C5-C4-H4 | 120.600 |
| C18-C20-H20A | 117.700 |
| C18-C20-H20B | 117.700 |
| H20A-C20-H20B | 114.800 |
| C19-C20-C18 | 60.52(17) |
| C19-C20-H20A | 117.700 |
| C19-C20-H20B | 117.700 |
| C18-C19-H19A | 117.600 |
| C18-C19-H19B | 117.600 |
| C20-C19-C18 | 61.41(18) |
| C20-C19-H19A | 117.600 |
| C20-C19-H19B | 117.600 |
| H19A-C19-H19B | 114.700 |


Table S6. Anisotropic displacement parameters ($\text{\AA}^2 \times 10^3$) for **3aa-8**


| Atom | U11 | U22 | U33 | U12 | U13 | U23 |
|------|------------|------------|------------|-------------|-------------|------------|
| O2 | 0.0248(8) | 0.0250(8) | 0.0319(8) | -0.0072(7) | -0.0052(7) | -0.0025(7) |
| O5 | 0.0278(9) | 0.0282(8) | 0.0264(8) | -0.0085(7) | -0.0029(7) | -0.0074(7) |
| O4 | 0.0491(11) | 0.0242(9) | 0.0324(9) | -0.0062(8) | -0.0139(8) | -0.0047(7) |
| O3 | 0.0481(11) | 0.0242(9) | 0.0395(10) | -0.0064(8) | -0.0016(8) | -0.0070(7) |
| O6 | 0.0536(11) | 0.0415(10) | 0.0433(10) | -0.0287(9) | 0.0061(9) | -0.0150(8) |
| O1 | 0.0767(14) | 0.0540(11) | 0.0395(10) | -0.0414(11) | -0.0229(10) | 0.0002(9) |
| N1 | 0.0300(11) | 0.0279(10) | 0.029(1) | -0.0109(8) | -0.0087(8) | -0.0040(8) |
| N4 | 0.0317(11) | 0.0252(10) | 0.0249(10) | -0.0053(8) | -0.0085(8) | -0.0062(8) |
| N3 | 0.0319(11) | 0.0265(10) | 0.0295(10) | -0.0063(9) | -0.0070(9) | -0.0056(8) |


| | | | | | | |
|-----|------------|------------|------------|-------------|-------------|-------------|
| N2 | 0.0309(11) | 0.0386(11) | 0.0306(11) | -0.0122(9) | -0.0040(9) | -0.0047(9) |
| C33 | 0.0283(12) | 0.0272(12) | 0.0245(11) | -0.0121(10) | -0.0018(10) | -0.0074(10) |
| C26 | 0.0263(12) | 0.0281(12) | 0.0253(11) | -0.0107(10) | -0.0074(10) | -0.0039(10) |
| C25 | 0.0233(12) | 0.0259(11) | 0.0268(11) | -0.0101(9) | -0.0055(9) | -0.0061(9) |
| C32 | 0.0262(12) | 0.0240(11) | 0.0246(11) | -0.0114(10) | -0.0021(9) | -0.0057(9) |
| C11 | 0.0320(13) | 0.0196(11) | 0.0314(12) | -0.0052(10) | -0.0049(10) | -0.0047(10) |
| C12 | 0.0292(12) | 0.0192(11) | 0.0281(12) | -0.0033(9) | -0.0055(10) | -0.0066(9) |
| C7 | 0.0281(13) | 0.0199(11) | 0.0295(12) | -0.0061(9) | -0.0037(10) | -0.0058(9) |
| C17 | 0.0285(13) | 0.0308(13) | 0.0283(12) | -0.008(1) | -0.0096(10) | -0.0061(10) |
| C1 | 0.0292(13) | 0.0268(12) | 0.0274(12) | -0.0046(10) | -0.0059(10) | -0.0079(10) |
| C37 | 0.0331(13) | 0.0252(12) | 0.0284(12) | -0.0092(10) | -0.0076(11) | -0.0003(10) |
| C27 | 0.0285(13) | 0.0275(12) | 0.0257(11) | -0.0102(10) | -0.0053(10) | -0.0077(10) |
| C15 | 0.0299(13) | 0.0272(12) | 0.0323(13) | -0.0036(10) | -0.0095(11) | -0.0093(10) |
| C31 | 0.0307(13) | 0.0298(12) | 0.0271(12) | -0.0138(10) | -0.0038(10) | -0.0078(10) |
| C16 | 0.0277(12) | 0.0205(11) | 0.0270(11) | -0.0057(9) | -0.0031(10) | -0.0033(9) |
| C8 | 0.0367(14) | 0.0296(12) | 0.0349(13) | -0.0112(11) | -0.0108(11) | -0.007(1) |
| C24 | 0.0304(13) | 0.0299(12) | 0.0268(12) | -0.0084(10) | -0.0068(10) | -0.0047(10) |
| C13 | 0.0356(14) | 0.0267(12) | 0.0264(12) | -0.0038(10) | -0.0035(10) | -0.0037(10) |
| C6 | 0.0371(14) | 0.0269(12) | 0.0308(12) | -0.0085(11) | -0.0094(11) | -0.0072(10) |
| C34 | 0.0335(13) | 0.0302(12) | 0.0302(12) | -0.009(1) | -0.0104(11) | -0.0031(10) |
| C35 | 0.0411(15) | 0.0357(13) | 0.0269(12) | -0.0148(12) | -0.0121(11) | -0.0033(11) |
| C38 | 0.0279(13) | 0.0287(12) | 0.0293(12) | -0.0074(10) | -0.0044(10) | -0.0076(10) |
| C23 | 0.0354(14) | 0.0398(14) | 0.0250(12) | -0.0114(11) | -0.0086(11) | -0.0064(11) |
| C14 | 0.0383(14) | 0.0316(13) | 0.0263(12) | -0.0033(11) | -0.0094(11) | -0.0042(10) |
| C10 | 0.0373(14) | 0.0258(12) | 0.0354(13) | -0.0121(11) | -0.0051(11) | -0.0018(10) |
| C28 | 0.0314(13) | 0.0358(13) | 0.0313(13) | -0.0061(11) | -0.0105(11) | -0.0074(11) |
| C36 | 0.0376(14) | 0.0330(13) | 0.0261(12) | -0.0150(11) | -0.0047(11) | -0.0093(10) |
| C22 | 0.0354(14) | 0.0348(13) | 0.0312(13) | -0.0083(11) | -0.0048(11) | -0.0135(11) |
| C2 | 0.0403(15) | 0.0371(14) | 0.0318(13) | -0.0101(11) | -0.0119(11) | -0.0076(11) |
| C30 | 0.0350(14) | 0.0343(13) | 0.0297(12) | -0.0084(11) | -0.0025(11) | -0.0142(11) |
| C18 | 0.0259(13) | 0.0283(12) | 0.0437(14) | -0.0079(10) | -0.0057(11) | -0.0067(11) |
| C21 | 0.0382(14) | 0.0289(12) | 0.0346(13) | -0.0042(11) | -0.0082(11) | -0.0111(11) |
| C29 | 0.0342(14) | 0.0348(13) | 0.0357(13) | -0.0016(11) | -0.0073(11) | -0.0123(11) |
| C9 | 0.0339(14) | 0.0318(13) | 0.0452(15) | -0.0158(11) | -0.0062(12) | -0.0060(11) |
| C40 | 0.0297(14) | 0.0394(14) | 0.0461(15) | -0.0089(11) | -0.0045(12) | -0.0155(12) |
| C39 | 0.0438(16) | 0.0402(15) | 0.0324(13) | -0.0110(12) | 0.0013(12) | -0.0083(12) |
| C3 | 0.0535(17) | 0.0423(15) | 0.0308(13) | -0.0122(13) | -0.0135(12) | 0.0011(12) |
| C5 | 0.0414(16) | 0.0516(16) | 0.0362(14) | -0.0240(13) | -0.0056(12) | -0.0017(13) |
| C4 | 0.0495(17) | 0.0447(15) | 0.0349(14) | -0.0212(14) | -0.0038(13) | 0.0035(12) |
| C20 | 0.0289(15) | 0.0395(15) | 0.093(2) | -0.0095(12) | -0.0150(15) | -0.0102(15) |
| C19 | 0.0538(18) | 0.0462(16) | 0.0552(18) | -0.0239(14) | 0.0101(15) | -0.0124(14) |


6. Characterization data of silver carboxylates **2a-1–2d-16**


 Silver(I) acetate (**2a-1**). Following the general procedure, **2a-1** was obtained as a gray solid (752 mg, 90%). ¹H NMR (400 MHz, Pyridine-*d*₅) δ 2.45 (s, 3H). ¹³C{¹H} NMR (100 MHz, Pyridine-*d*₅) δ 176.4, 24.6.


 Silver(I) propionate (**2a-2**). Following the general procedure, **2a-2** was obtained as a gray solid (819 mg, 91%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.12 (q, *J* = 7.6 Hz, 2H), 1.01 (t, *J* = 7.6 Hz, 3H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 178.2, 30.2, 11.7.


 Silver(I) butyrate (**2a-3**). Following the general procedure, **2a-3** was obtained as a gray solid (873 mg, 90%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.10 (t, *J* = 7.4 Hz, 2H), 1.58-1.46 (m, 2H), 0.86 (t, *J* = 7.4 Hz, 3H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 177.4, 39.3, 20.2, 14.6.


 Silver(I) isobutyrate (**2a-4**). Following the general procedure, **2a-4** was obtained as a gray solid (922 mg, 95%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.39 (sep, *J* = 6.8 Hz, 1H), 1.05 (d, *J* = 6.8 Hz, 6H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 180.9, 36.2, 21.2.

 Silver(I) pivalate (**2a-5**). Following the general procedure, **2a-5** was obtained as a gray solid (1009 mg, 97%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 1.10 (s, 9H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 182.3, 39.6, 29.4.


 Silver(I) nonanoate (**2a-6**). Following the general procedure, **2a-6** was obtained as a white solid (2124 mg, 80%). ¹H NMR (400 MHz, Pyridine-*d*₅) δ 2.82 (t, *J* = 7.6 Hz, 2H), 2.12-2.04 (m, 2H), 1.57-1.47 (m, 2H), 1.35-1.27 (m, 2H), 1.25-1.11 (m, 6H), 0.79 (t, *J* = 6.8 Hz, 3H). ¹³C{¹H} NMR (100 MHz, Pyridine-*d*₅) δ 179.0, 38.5, 32.0, 30.4, 30.0, 29.6, 28.0, 22.8, 14.2.

 Silver(I) adamantane-1-carboxylate (**2a-7**). Following the general procedure, **2a-7** was obtained as a gray solid (1148 mg, 80%). ¹H NMR (400 MHz, Pyridine-*d*₅) δ 2.49-2.43 (m, 6H), 2.03 (s, 3H), 1.81 (s, 1H), 1.78 (s, 2H), 1.73 (s, 2H), 1.70 (s, 1H). ¹³C{¹H} NMR (100 MHz, Pyridine-*d*₅) δ 183.2, 42.1, 41.6, 37.5, 39.3.


 Silver(I) cyclopropanecarboxylate (**2a-8**). Following the general procedure, **2a-8** was obtained as a gray solid (682 mg, 71%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 1.51-1.38 (m, 1H), 0.69-0.54 (m, 4H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 178.5, 15.6, 7.3.




Silver(I) cyclobutanecarboxylate (**2a-9**). Following the general procedure, **2a-9** was obtained as a gray solid (618 mg, 60%). ^1H NMR (400 MHz, DMSO- d_6) δ 3.03-2.91 (m, 1H), 2.16-2.00 (m, 4H), 1.88-1.68 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, DMSO- d_6) δ 179.4, 40.8, 26.7, 18.2.




Silver(I) cyclopentanecarboxylate (**2a-10**). Following the general procedure, **2a-10** was obtained as a gray solid (880 mg, 80%). ^1H NMR (400 MHz, DMSO- d_6) δ 2.63-2.53 (m, 1H), 1.80-1.36 (m, 8H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, DMSO- d_6) δ 180.3, 46.5, 31.2, 25.9.




Silver(I) cyclohexanecarboxylate (**2a-11**). Following the general procedure, **2a-11** was obtained as a gray solid (995 mg, 85%). ^1H NMR (400 MHz, DMSO- d_6) δ 2.14-2.04 (m, 1H), 1.78-1.74 (m, 2H), 1.70-1.60 (m, 2H), 1.59-1.52 (m, 1H), 1.35-1.13 (m, 5H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, DMSO- d_6) δ 179.8, 45.5, 30.9, 26.4, 26.1.




Silver(I) 2-(naphthalen-1-yl)acetate (**2a-12**). Following the general procedure, **2a-12** was obtained as a gray solid (1241 mg, 85%). ^1H NMR (400 MHz, DMSO- d_6) δ 8.12-7.99 (m, 1H), 7.94-7.83 (m, 1H), 7.75 (d, $J = 8.0$ Hz, 1H), 7.51-7.43 (m, 2H), 7.43-7.31 (m, 2H), 3.91 (s, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, DMSO- d_6) δ 175.4, 135.3, 133.8, 132.7, 128.6, 127.9, 126.8, 126.1, 125.9, 125.8, 125.2, 42.3.



Silver(I) 2,2,3,3-tetramethylcyclopropane-1-carboxylate (**2a-13**). Following the general procedure, **2a-13** was obtained as a gray solid (930 mg, 75%). ^1H NMR (400 MHz, DMSO- d_6) δ 1.19 (s, 6H), 1.13 (s, 1H), 1.08 (s, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, DMSO- d_6) δ 176.7, 26.3, 24.4, 17.9.




Silver(I) 3-(2-bromophenyl)propanoate (**2a-14**). Following the general procedure, **2a-14** was obtained as a gray solid (1598 mg, 80%). ^1H NMR (400 MHz, Pyridine- d_5) δ 7.57-7.49 (m, 2H), 7.14 (t, $J = 7.2$ Hz, 1H), 6.99 (t, $J = 7.6$ Hz, 1H), 3.54 (t, $J = 8.0$ Hz, 2H), 3.11 (t, $J = 8.0$ Hz, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, Pyridine- d_5) δ 176.3, 141.6, 131.3, 129.5, 126.4, 126.2, 123.4, 36.8, 33.0.




Silver(I) 2-methylbenzoate (**2b-1**). Following the general procedure, **2b-1** was obtained as a gray solid (1150 mg, 95%). ^1H NMR (400 MHz, DMSO- d_6) δ 7.65 (d, $J = 8.0$ Hz, 1H), 7.24-7.19 (m, 1H), 7.18-7.08 (m, 2H), 2.49 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, DMSO- d_6) δ 173.2, 138.8,


136.9, 130.9, 129.7, 129.0, 125.5, 21.8.




Silver(I) 2-methoxybenzoate (**2b-2**). Following the general procedure, **2b-2** was obtained as a gray solid (1226 mg, 95%). ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 7.43 (dd, $J = 7.6, 2.0$ Hz, 1H), 7.31-7.25 (m, 1H), 6.98 (dd, $J = 8.4, 1.2$ Hz, 1H), 6.89 (dt, $J = 7.6, 1.2$ Hz, 1H), 3.73 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, $\text{DMSO-}d_6$) δ 171.8, 156.7, 129.9, 129.7, 129.4, 120.2, 112.2, 55.8.




Silver(I) 2-acetylbenzoate (**2b-3**). Following the general procedure, **2b-3** was obtained as a gray solid (1283 mg, 95%). ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 8.03 (d, $J = 8.4$ Hz, 2H), 7.95 (d, $J = 8.4$ Hz, 2H), 2.59 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, $\text{DMSO-}d_6$) δ 198.3, 169.7, 141.8, 138.2, 130.0, 128.2, 27.4.




Silver(I) 2-cyanobenzoate (**2b-4**). Following the general procedure, **2b-4** was obtained as a gray solid (1201 mg, 95%). ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 8.02 (dd, $J = 7.6, 1.2$ Hz, 1H), 7.77 (dd, $J = 7.6, 1.2$ Hz, 1H), 7.66 (dt, $J = 7.6, 1.2$ Hz, 1H), 7.55 (dd, $J = 7.6, 1.2$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, $\text{DMSO-}d_6$) δ 168.2, 141.5, 134.3, 132.7, 131.0, 130.4, 119.7, 112.1.




Silver(I) 3-methylbenzoate (**2b-5**). Following the general procedure, **2b-5** was obtained as a gray solid (1138 mg, 94%). ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 7.78 (s, 1H), 7.75 (d, $J = 6.4$ Hz, 1H), 7.29-7.21 (m, 2H), 2.34 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, $\text{DMSO-}d_6$) δ 170.8, 137.21, 137.19, 131.3, 130.7, 128.1, 127.2, 21.5.




Silver(I) 3-methoxybenzoate (**2b-6**). Following the general procedure, **2b-6** was obtained as a gray solid (1226 mg, 95%). ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 7.60-7.40 (m, 2H), 7.32-7.23 (m, 1H), 7.05-6.92 (m, 1H), 3.77 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, $\text{DMSO-}d_6$) δ 170.4, 159.3, 136.2, 129.3, 122.4, 116.6, 114.9, 55.5.




Silver(I) 3-acetylbenzoate (**2b-7**). Following the general procedure, **2b-7** was obtained as a gray solid (1242 mg, 92%). ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 8.51 (s, 1H), 8.18 (d, $J = 7.6$ Hz, 1H), 8.02 (d, $J = 7.6$ Hz, 1H), 7.54 (t, $J = 7.6$ Hz, 1H), 2.60 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, $\text{DMSO-}d_6$) δ 198.3, 169.7, 137.9, 137.0, 134.4, 130.3, 129.5, 128.7, 27.3.




Silver(I) 3-cyanobenzoate (**2b-8**). Following the general procedure, **2b-8** was obtained as a gray solid (1213 mg, 96%). ^1H NMR (400 MHz, DMSO- d_6) δ 8.24-8.18 (m, 2H), 7.90-7.85 (m, 1H), 7.60 (t, J = 8.0 Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, DMSO- d_6) δ 168.5, 139.0, 134.4, 133.9, 133.2, 129.7, 129.3, 111.3.




Silver(I) benzoate (**2b-9**). Following the general procedure, **2b-9** was obtained as a gray solid (1053 mg, 93%). ^1H NMR (400 MHz, Pyridine- d_5) δ 8.85 (d, J = 8.0 Hz, 2H), 7.49-7.38 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, Pyridine- d_5) δ 171.8, 140.2, 130.6, 129.5, 127.8.




Silver(I) 4-methylbenzoate (**2b-10**). Following the general procedure, **2b-10** was obtained as a gray solid (1150 mg, 95%). ^1H NMR (400 MHz, DMSO- d_6) δ 7.85 (d, J = 8.0 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 2.33 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, DMSO- d_6) δ 170.7, 140.3, 134.5, 130.1, 128.8, 21.5.




Silver(I) 4-methoxybenzoate (**2b-11**). Following the general procedure, **2b-11** was obtained as a gray solid (1225 mg, 95%). ^1H NMR (400 MHz, DMSO- d_6) δ 7.89 (d, J = 9.0 Hz, 2H), 6.89 (d, J = 9.0 Hz, 2H), 3.78 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, DMSO- d_6) δ 170.5, 161.4, 131.8, 129.7, 113.4, 55.6.




Silver(I) 4-phenoxybenzoate (**2b-12**). Following the general procedure, **2b-12** was obtained as a gray solid (1225 mg, 95%). ^1H NMR (400 MHz, DMSO- d_6) δ 7.96 (d, J = 8.8 Hz, 2H), 7.42 (dd, J = 8.8, 7.2 Hz, 2H), 7.18 (t, J = 7.2 Hz, 1H), 7.07 (d, J = 7.2 Hz, 2H), 6.95 (d, J = 8.8 Hz, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, DMSO- d_6) δ 170.0, 159.2, 156.4, 132.2, 132.1, 130.6, 124.4, 119.8, 117.4.




Silver(I) 4-acetylbenzoate (**2b-13**). Following the general procedure, **2b-13** was obtained as a gray solid (1245 mg, 92%). ^1H NMR (400 MHz, DMSO- d_6) δ 8.04 (d, J = 8.2 Hz, 2H), 7.98 (d, J = 8.2 Hz, 2H), 2.60 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, DMSO- d_6) δ 198.3, 168.8, 139.6, 138.9, 130.0, 128.4, 27.4.




Silver(I) 4-chlorobenzoate (**2b-14**). Following the general procedure, **2b-14** was obtained as a gray solid (1179 mg, 90%). ^1H NMR (400 MHz, DMSO- d_6) δ 7.95 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 8.4 Hz, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, DMSO- d_6) δ 169.1, 136.0, 135.1, 131.8, 128.5.




Silver(I) 4-cyanobenzoate (**2b-15**). Following the general procedure, **2b-15** was obtained as a gray solid (1175 mg, 93%). ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 8.06 (d, $J = 8.0$ Hz, 2H), 7.84 (d, $J = 8.0$ Hz, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, $\text{DMSO-}d_6$) δ 169.0, 142.0, 132.4, 130.5, 119.3, 112.8.




Silver(I) 4-(trifluoromethyl)benzoate (**2b-16**). Following the general procedure, **2b-16** was obtained as a gray solid (1406 mg, 95%). ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 8.13 (d, $J = 8.0$ Hz, 2H), 7.73 (d, $J = 8.0$ Hz, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, $\text{DMSO-}d_6$) δ 169.3, 141.4, 130.7 (q, $J_{\text{C-F}} = 31.3$ Hz), 130.6, 125.2 (q, $J_{\text{C-F}} = 14.0$ Hz), 124.7 (q, $J_{\text{C-F}} = 270.6$ Hz). ^{19}F NMR (376 MHz, $\text{DMSO-}d_6$) δ -61.1.




Silver(I) 4-nitrobenzoate (**2b-17**). Following the general procedure, **2b-17** was obtained as a gray solid (1256 mg, 92%). ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 8.21 (d, $J = 8.8$ Hz, 2H), 8.12 (d, $J = 8.8$ Hz, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, $\text{DMSO-}d_6$) δ 168.6, 148.8, 144.2, 130.9, 123.4.




Silver(I) furan-2-carboxylate (**2b-18**). Following the general procedure, **2b-18** was obtained as a gray solid (872 mg, 80%). ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 7.65 (dd, $J = 1.6, 0.8$ Hz, 1H), 6.81 (dd, $J = 3.2, 0.8$ Hz, 1H), 6.48 (dd, $J = 3.2, 1.6$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, $\text{DMSO-}d_6$) δ 163.2, 151.7, 144.2, 113.8, 111.6.




Silver(I) oxazole-2-carboxylate (**2b-19**). Following the general procedure, **2b-19** was obtained as a gray solid (876 mg, 80%). ^1H NMR (400 MHz, $\text{Pyridine-}d_5$) δ 7.97 (s, 1H), 7.24 (s, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, $\text{Pyridine-}d_5$) δ 162.9, 159.6, 139.9, 127.5.




Silver(I) thiophene-2-carboxylate (**2b-20**). Following the general procedure, **2b-20** was obtained as a gray solid (936 mg, 80%). ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 7.58 (dd, $J = 4.8, 1.2$ Hz, 1H), 7.47 (dd, $J = 3.6, 1.2$ Hz, 1H), 7.05 (dd, $J = 4.8, 3.6$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, $\text{DMSO-}d_6$) δ 166.2, 143.0, 130.6, 130.3, 127.9.




Silver(I) thiazole-2-carboxylate (**2b-21**). Following the general procedure, **2b-21** was obtained as a gray solid (940 mg, 80%). ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 7.91 (d, $J = 3.2$ Hz, 1H), 7.88 (d, $J = 3.2$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, $\text{DMSO-}d_6$) δ 172.4, 160.8, 143.0, 125.5.




Silver(I) furan-3-carboxylate (**2b-22**). Following the general procedure, **2b-22** was obtained as a gray solid (894 mg, 83%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.94 (dd, *J* = 1.6, 0.8 Hz, 1H), 7.60 (t, *J* = 1.6 Hz, 1H), 6.60 (dd, *J* = 1.6, 0.8 Hz, 1H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 167.3, 146.1, 143.6, 125.5, 111.7.




Silver(I) oxazole-4-carboxylate (**2b-23**). Following the general procedure, **2b-23** was obtained as a gray solid (876 mg, 80%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.52 (d, *J* = 0.8 Hz, 1H), 8.45 (d, *J* = 0.8 Hz, 1H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 163.1, 152.7, 143.5, 136.3.




Silver(I) thiophene-3-carboxylate (**2b-24**). Following the general procedure, **2b-24** was obtained as a gray solid (937 mg, 80%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.91 (dd, *J* = 3.2, 0.8 Hz, 1H), 7.44 (dd, *J* = 4.8, 3.2 Hz, 1H), 7.37 (dd, *J* = 4.8, 0.8 Hz, 1H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 167.3, 141.3, 129.9, 129.5, 125.8.




Silver(I) thiazole-4-carboxylate (**2b-25**). Following the general procedure, **2b-25** was obtained as a gray solid (942 mg, 80%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 9.20 (d, *J* = 2.0 Hz, 1H), 8.39 (d, *J* = 2.0 Hz, 1H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 163.6, 156.7, 150.8, 127.0.




Silver(I) picolinate (**2b-26**). Following the general procedure, **2b-26** was obtained as a gray solid (1031 mg, 91%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.69 (d, *J* = 4.4 Hz, 1H), 8.06 (d, *J* = 7.6 Hz, 1H), 7.99 (dt, *J* = 7.6, 1.6 Hz, 1H), 7.66-7.59 (m, 1H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 166.6, 150.0, 149.3, 138.1, 127.4, 125.1.




Silver(I) nicotinate (**2b-27**). Following the general procedure, **2b-27** was obtained as a gray solid (912 mg, 80%). ¹H NMR (400 MHz, Pyridine-*d*₅) δ 10.10 (d, *J* = 2.0 Hz, 1H), 8.91 (dt, *J* = 7.6, 2.0 Hz, 1H), 8.72 (dd, *J* = 4.8, 2.0 Hz, 1H), 7.27 (dd, *J* = 7.6, 4.8 Hz, 1H). ¹³C{¹H} NMR (100 MHz, Pyridine-*d*₅) δ 170.1, 152.4, 150.4, 137.5, 123.0.




Silver(I) isonicotinate (**2b-28**). Following the general procedure, **2b-28** was obtained as a gray solid (1005 mg, 88%). ¹H NMR (400 MHz, Pyridine-*d*₅) δ 8.85 (dt, *J* = 4.0, 2.0 Hz, 2H), 8.52 (dt, *J* = 4.0, 2.0 Hz, 2H). ¹³C{¹H} NMR (100 MHz, Pyridine-*d*₅) δ 169.9, 150.2, 147.8, 124.7.




Silver(I) 2-naphthoate (**2b-29**). Following the general procedure, **2b-29** was obtained as a gray solid (1181 mg, 85%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.55 (s, 1H), 8.07 (dd, *J* = 8.4, 1.4 Hz, 1H), 8.05-8.00 (m, 1H), 7.96-7.92 (m, 1H), 7.90 (d, *J* = 8.8 Hz, 1H), 7.60-7.50 (m, 2H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 170.5, 134.5, 134.3, 132.9, 130.0, 129.4, 127.9, 127.6, 127.5, 127.3, 126.6.




Silver(I) quinoline-2-carboxylate (**2b-30**). Following the general procedure, **2b-30** was obtained as a gray solid (1173 mg, 84%). ¹H NMR (400 MHz, Pyridine-*d*₅) δ 9.03 (d, *J* = 8.8 Hz, 1H), 8.64 (d, *J* = 8.4 Hz, 1H), 8.32 (d, *J* = 8.4 Hz, 1H), 7.86 (d, *J* = 8.0 Hz, 1H), 7.70-7.64 (m, 1H), 7.53-7.47 (m, 1H). ¹³C{¹H} NMR (100 MHz, Pyridine-*d*₅) δ 168.2, 156.6, 146.1, 137.8, 130.4, 130.3, 129.3, 128.1, 127.6, 123.0.




Silver(I) 1-naphthoate (**2b-31**). Following the general procedure, **2b-31** was obtained as a gray solid (1188 mg, 86%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.97-8.88 (m, 1H), 7.98-7.87 (m, 3H), 7.55-7.44 (m, 3H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 172.7, 136.9, 133.9, 131.2, 129.7, 128.4, 127.8, 127.7, 126.3, 125.9, 125.5.




Silver(I) benzo[d][1,3]dioxole-5-carboxylate (**2b-32**). Following the general procedure, **2b-32** was obtained as a gray solid (1292 mg, 95%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.54 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.38 (d, *J* = 1.6 Hz, 1H), 6.89 (d, *J* = 8.0 Hz, 1H), 6.05 (s, 2H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 169.7, 149.6, 147.3, 131.1, 124.8, 109.9, 107.9, 101.7.




Silver(I) acrylate (**2c-1**). Following the general procedure, **2c-1** was obtained as a gray solid (712 mg, 80%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 6.15 (dd, *J* = 17.2, 10.0 Hz, 1H), 5.97 (dd, *J* = 17.2, 2.8 Hz, 1H), 5.52 (dd, *J* = 10.0, 2.8, 1H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 170.7, 135.7, 125.4.





Silver(I) methacrylate (**2c-2**). Following the general procedure, **2c-2** was obtained as a gray solid (772 mg, 81%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 5.76 (dd, *J* = 7.2, 4.8, 1H), 5.26-5.22 (m, 1H), 1.86 (s, 3H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 172.0, 143.6, 120.6, 20.8.





Silver(I) cinnamate (**2c-3**). Following the general procedure, **2c-3** was obtained as a gray solid (1143 mg, 90%). ¹H NMR (400 MHz, Pyridine-*d*₅) δ 8.17 (d, *J* = 16.0 Hz, 1H), 7.59 (d, *J* = 7.2 Hz, 2H), 7.43 (d, *J* = 16.0 Hz, 1H), 7.29-7.18 (m, 3H). ¹³C{¹H} NMR (100 MHz, Pyridine-*d*₅) δ 172.6, 138.1, 137.5, 129.3, 128.9, 128.3, 127.5.



 Silver(I) 3-(*p*-tolyl)acrylate (**2c-4**). Following the general procedure, **2c-4** was obtained as a gray solid (1206 mg, 90%). ¹H NMR (400 MHz, Pyridine-*d*₅) δ 8.17 (d, *J* = 15.6 Hz, 1H), 7.52 (d, *J* = 8.0 Hz, 2H), 7.39 (d, *J* = 15.6 Hz, 1H), 7.07 (d, *J* = 8.0 Hz, 2H), 2.15 (s, 3H). ¹³C{¹H} NMR (100 MHz, Pyridine-*d*₅) δ 172.5, 138.5, 138.2, 134.6, 129.6, 127.63, 127.59, 21.0.


 Silver(I) 3-(4-methoxyphenyl)acrylate (**2c-5**). Following the general procedure, **2c-5** was obtained as a gray solid (1278 mg, 90%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.60 (d, *J* = 8.8 Hz, 2H), 7.46 (d, *J* = 16.0 Hz, 1H), 7.00 (d, *J* = 8.8 Hz, 2H), 6.38 (d, *J* = 16.0 Hz, 1H), 3.79 (s, 3H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 168.9, 161.1, 142.8, 130.1, 127.7, 118.8, 114.8, 55.7.



 Silver(I) 3-(4-(trifluoromethyl)phenyl)acrylate (**2c-6**). Following the general procedure, **2c-6** was obtained as a gray solid (1450 mg, 90%). ¹H NMR (400 MHz, Pyridine-*d*₅) δ 8.09 (d, *J* = 16.0 Hz, 1H), 7.65 (d, *J* = 8.0 Hz, 2H), 7.55 (d, *J* = 8.0 Hz, 2H), 7.47 (d, *J* = 16.0 Hz, 1H). ¹³C{¹H} NMR (100 MHz, Pyridine-*d*₅) δ 171.5, 141.2, 136.9, 131.3, 129.3 (q, *J*_{C-F} = 31.8 Hz), 127.9, 125.7 (q, *J*_{C-F} = 3.8 Hz), 124.8 (q, *J*_{C-F} = 270.2 Hz). ¹⁹F NMR (376 MHz, Pyridine-*d*₅) δ -61.9.


 Silver(I) 3-(2-bromophenyl)acrylate (**2c-7**). Following the general procedure, **2c-7** was obtained as a gray solid (1560 mg, 92%). ¹H NMR (400 MHz, Pyridine-*d*₅) δ 8.49 (d, *J* = 15.6 Hz, 1H), 7.75 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.55 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.28 (d, *J* = 15.6 Hz, 1H), 7.19 (t, *J* = 7.6 Hz, 1H), 7.06 (dt, *J* = 7.6, 1.6 Hz, 1H). ¹³C{¹H} NMR (100 MHz, Pyridine-*d*₅) δ 171.2, 137.5, 136.6, 133.3, 130.4, 130.0, 128.00, 127.98, 124.7.



 Silver(I) (*R*)-2-((1*R*,4*R*,4*aS*,8*aS*)-4,7-dimethyl-1,2,3,4,4*a*,5,6,8*a*-octahydrophthalen-1-yl)propanoate (**2d-1**). Following the general procedure, **2d-1** was obtained as a gray solid (1368 mg, 80%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 5.17 (s, 1H), 2.45-2.30 (m, 2H), 1.92-1.71 (m, 3H), 1.60 (s, 3H), 1.54-1.43 (m, 3H), 1.40-1.29 (m, 2H), 1.21-1.14 (m, 1H), 1.02-0.95 (m, 3H), 0.89-0.73 (m, 5H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 180.6, 134.9, 120.7, 44.7, 44.4, 41.8, 36.6, 35.6, 28.0, 27.9, 26.7, 25.9, 24.2, 20.2, 16.6.




Silver(I) (*S*)-2-(6-methoxynaphthalen-2-yl)propanoate (**2d-2**). Following the general procedure, **2d-2** was obtained as a gray solid (1182 mg, 83%). ¹H NMR (400 MHz, Pyridine-*d*₅) δ 8.19 (s, 1H), 8.12 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.83 (d, *J* = 8.4 Hz, 1H), 7.74 (d, *J* = 8.8 Hz, 1H), 7.30 (d, *J* = 2.4 Hz, 1H), 7.24 (dd, *J* = 8.8, 2.4 Hz, 1H), 4.43 (q, *J* = 7.2 Hz, 1H), 3.76 (s, 3H), 1.97 (d, *J* = 7.2 Hz, 3H). ¹³C{¹H} NMR (100 MHz, Pyridine-*d*₅) δ 179.3, 157.4, 142.2, 133.7, 126.7, 129.5, 128.5, 126.6, 126.1, 118.6, 106.1, 55.1, 49.5, 21.1.




Silver(I) 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate (**2d-3**). Following the general procedure, **2d-3** was obtained as a gray solid (1950 mg, 92%). ¹H NMR (400 MHz, Pyridine-*d*₅) δ 7.73 (d, *J* = 9.2 Hz, 2H), 7.66 (d, *J* = 8.4 Hz, 2H), 7.49-7.41 (m, 4H), 2.07 (s, 6H). ¹³C{¹H} NMR (100 MHz, Pyridine-*d*₅) δ 193.7, 177.1, 162.8, 137.54, 137.50, 132.1, 131.3, 128.6, 128.4, 117.6, 82.8, 27.2.



Silver(I) hexa-2,4-dienoate (**2d-4**). Following the general procedure, **2d-4** was obtained as a gray solid (937 mg, 86%). ¹H NMR (400 MHz, Pyridine-*d*₅) δ 7.73 (dd, *J* = 15.2, 10.8 Hz, 1H), 6.73 (d, *J* = 15.2 Hz, 1H), 6.33-6.23 (m, 1H), 5.86-5.75 (m, 1H), 1.58 (d, *J* = 6.8 Hz, 3H). ¹³C{¹H} NMR (100 MHz, Pyridine-*d*₅) δ 171.2, 146.7, 140.0, 134.7, 131.1, 13.7.




Silver(I) 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate (**2d-5**). Following the general procedure, **2d-5** was obtained as a gray solid (1730 mg, 82%). ¹H NMR (400 MHz, Pyridine-*d*₅) δ 8.47 (d, *J* = 2.0 Hz, 1H), 8.23 (dd, *J* = 8.8, 2.0 Hz, 1H), 7.03 (d, *J* = 8.8 Hz, 1H), 3.76 (d, *J* = 6.8 Hz, 2H), 3.25 (s, 3H), 2.07-1.95 (m, 1H), 0.96 (d, *J* = 6.8 Hz, 6H). ¹³C{¹H} NMR (100 MHz, Pyridine-*d*₅) δ 166.8, 163.2, 161.7, 155.0, 132.5, 131.6, 127.8, 116.3, 113.3, 102.6, 75.5, 28.2, 18.9, 17.3.



Silver(I) (*1R,3R*)-3-((*Z*)-2-chloro-3,3,3-trifluoroprop-1-en-1-yl)-2,2-dimethylcyclopropane-1-carboxylate (**2d-6**). Following the general procedure, **2d-6** was obtained as a gray solid (1566 mg, 90%). ¹H NMR (400 MHz, Pyridine-*d*₅) δ 8.30 (d, *J* = 9.6 Hz, 1H), 2.64 (d, *J* = 8.0 Hz, 1H), 2.10 (t, *J* = 9.2 Hz, 1H), 1.60 (s, 3H), 1.20 (s, 3H). ¹³C{¹H} NMR (100 MHz, Pyridine-*d*₅) δ 174.9, 137.1 (q, *J*_{C-F} = 4.4 Hz), 121.8 (q, *J*_{C-F} = 274.4 Hz), 116.9 (q,


$J_{C-F} = 36.5$ Hz), 39.5, 30.3, 28.9, 27.3, 16.3. ^{19}F NMR (376 MHz, Pyridine- d_5) δ -67.2.



2d-7

Silver(I)

3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoate (**2d-7**). Following the general procedure, **2d-7** was obtained as a gray solid (1624 mg, 80%). ^1H NMR (400 MHz, DMSO- d_6) δ 6.90 (dd, $J = 15.2, 11.6$ Hz, 1H), 6.37 (d, $J = 15.2$ Hz, 1H), 6.26-6.11 (m, 3H), 5.82 (s, 1H), 2.24 (s, 3H), 2.00 (t, $J = 6.0$ Hz, 2H), 1.96 (s, 3H), 1.68 (s, 3H), 1.60-1.54 (m, 2H), 1.46-1.41 (m, 2H), 1.01 (s, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, DMSO- d_6) δ 170.1, 138.2, 137.8, 137.6, 136.9, 130.6, 129.7, 129.63, 129.62, 127.7, 39.7, 34.4, 33.1, 29.3, 22.0, 19.2, 13.9, 13.1.




2d-8

Silver(I) benzoylglycinate (**2d-8**). Following the general procedure, **2d-8** was obtained as a gray solid (1182 mg, 83%).

^1H NMR (400 MHz, DMSO- d_6) δ 8.47 (t, $J = 5.6$ Hz, 1H), 7.88-7.82 (m, 2H), 7.53-7.41 (m, 3H), 3.81 (d, $J = 5.6$ Hz, 2H).


$^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, DMSO- d_6) δ 173.6, 166.1, 135.1, 131.5, 128.7, 127.6, 44.0.



3d-9

Silver(I)


(1*R*,4*aR*,4*bR*,10*aR*)-7-isopropyl-1,4*a*-dimethyl-1,2,3,4,4*a*,4*b*,5,6,10,10*a*-decahydrophenanthrene-1-carboxylate (**2d-9**). Following the general procedure, **2d-9** was obtained as a gray solid (1773 mg, 90%). ^1H NMR (400 MHz, DMSO- d_6) δ 5.74 (s, 1H), 5.35 (s, 1H), 2.34-2.12 (m, 2H), 2.09-2.01 (m, 3H), 1.84-1.70 (m, 6H), 1.51-1.43 (m, 4H), 1.54 (s, 3H), 0.97 (dd, $J = 6.8, 1.2$ Hz, 6H), 0.74 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, DMSO- d_6) δ 182.0, 144.4, 135.2, 123.0, 121.7, 51.1, 47.1, 46.1, 38.8, 38.5, 34.7, 34.6, 27.3, 25.9, 22.5, 21.8, 21.2, 19.0, 18.8, 14.3.



3d-10


Silver(I)

5-ethyl-8-oxo-5,8-dihydro-[1,3]dioxolo[4,5-*g*]quinoline-7-carboxylate (**2d-10**). Following the general procedure, **2d-10** was obtained as a gray solid (1508 mg, 82%). ^1H NMR (400 MHz, Pyridine- d_5) δ 9.07 (s, 1H), 8.26 (s, 1H), 7.14 (s, 1H), 6.08 (s, 2H), 4.17-3.91 (m, 2H), 1.14 (t, $J = 6.8$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, Pyridine- d_5) δ 175.2, 170.8, 152.0, 146.7, 145.7, 136.3, 125.2, 104.5, 102.5, 95.8, 48.5, 14.3.



Silver(I)

(*R*)-4-((5*S*,8*R*,9*S*,10*S*,13*R*,14*S*,17*R*)-10,13-dimethyl-3,7,12-trioxohexadecahydro-1*H*-cyclopenta[*a*]phenanthren-17-yl)pentanoate (**2d-11**). Following the general procedure, **2d-11** was obtained as a gray solid (2088 mg, 80%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 3.07-2.94 (m, 2H), 2.83 (t, *J* = 12.6 Hz, 1H), 2.43 (dt, *J* = 12.4, 5.2 Hz, 1H), 2.34-1.92 (m, 9H), 1.87-1.63 (m, 6H), 1.49 (dt, *J* = 14.4, 4.0 Hz, 1H), 1.32 (s, 3H), 1.29-1.19 (m, 4H), 1.00 (s, 3H), 0.75 (d, *J* = 5.6 Hz, 3H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 212.8, 210.4, 210.3, 178.2, 55.8, 51.8, 48.6, 46.6, 46.2, 45.1, 44.7, 43.1, 39.0, 36.7, 36.2, 35.9, 35.1, 34.5, 32.9, 27.9, 25.2, 21.7, 19.5, 12.1.




Silver(I)

2-(2-((2,6-dichlorophenyl)amino)phenyl)acetate


(**2d-12**). Following the general procedure, **2d-12** was obtained as a gray solid (1602 mg, 80%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.98 (s, 1H), 7.47 (d, *J* = 8.0 Hz, 2H), 7.15-7.07 (m, 2H), 6.98 (dt, *J* = 8.0, 1.6 Hz, 1H), 6.79 (dt, *J* = 7.2, 1.6 Hz, 1H), 6.28 (dd, *J* = 8.0, 1.2 Hz, 1H), 3.56 (s, 2H). ¹³C{¹H} NMR (100 MHz,

DMSO-*d*₆) δ 176.0, 143.3, 138.1, 130.7, 129.6, 129.4, 127.6, 126.8, 124.8, 120.9, 116.4, 42.6.




Silver(I) 2-oxo-2H-pyran-5-carboxylate (**2d-13**). Following the general procedure, **2d-13** was obtained as a gray solid (984 mg, 80%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.26 (dd, *J* = 2.6, 1.0 Hz, 1H), 7.88 (dd, *J* = 9.6, 2.6 Hz, 1H), 6.28 (dd, *J* = 9.6, 1.0 Hz).

¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 166.4, 161.4, 156.7, 145.7, 117.4, 114.0.




Silver(I) 4-oxo-4H-pyran-2-carboxylate (**2d-14**). Following the general procedure, **2d-14** was obtained as a gray solid (1082 mg, 88%). ¹H NMR (400 MHz, Pyridine-*d*₅) δ 8.04 (d, *J* = 5.6 Hz, 1H), 7.62 (d, *J* = 2.8 Hz, 1H), 6.45 (dd, *J* = 5.6, 2.8 Hz, 1H). ¹³C{¹H}

NMR (100 MHz, Pyridine-*d*₅) δ 179.9, 163.5, 161.0, 155.8, 117.7, 117.5.




Silver(I) 2-oxopropanoate (**2d-15**). Following the general procedure, **2d-15** was obtained as a gray solid (873 mg, 90%). ¹H NMR (400 MHz, DMSO-*d*₆) δ 2.20 (s, 3H). ¹³C{¹H} NMR (100 MHz, DMSO-*d*₆) δ 203.0, 169.5, 27.8.




Silver(I) 4-oxo-4-(2,4,5-triethoxyphenyl)butanoate (**2d-16**). Following the general procedure, **2d-16** was obtained as a gray solid (1893 mg, 91%). ¹H NMR (400 MHz, Pyridine-*d*₅) δ 7.80 (s, 1H), 6.65 (s, 1H), 4.06 (q, *J* = 6.8 Hz, 2H), 4.01 (q, *J* = 6.8

Hz, 2H), 3.92-3.85 (m, 4H), 3.37 (t, $J = 6.8$ Hz, 2H), 1.37 (t, $J = 6.8$ Hz, 3H), 1.32 (t, $J = 6.8$ Hz, 3H), 1.23 (t, $J = 6.8$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, Pyridine- d_5) δ 200.5, 178.1, 154.8, 153.7, 142.9, 120.7, 115.8, 99.5, 65.0, 64.9, 64.5, 42.3, 33.1, 15.0, 14.83, 14.76.


7. Characterization data of products **3aa-1–3wa**



8-(Picolinamido)naphthalen-1-yl acetate (**3aa-1**). Following the general procedure, **3aa-1** was obtained as a colorless solid (56.4 mg, 92%). $R_f = 0.40$ (n-hexane/EtOAc 3:1). m.p. 160.0–162.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 11.52 (s, 1H), 8.77 (d, $J = 7.6$ Hz, 1H), 8.68-8.62 (m, 1H), 8.38 (d, $J = 8.0$ Hz, 1H), 7.97-7.10 (m, 1H), 7.76 (d, $J = 8.0$ Hz, 1H), 7.69 (d, $J = 8.0$ Hz, 1H), 7.56-7.49 (m, 2H), 7.46 (t, $J = 8.0$ Hz, 1H), 7.20 (d, $J = 7.6$ Hz, 1H), 2.46 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.6, 162.3, 150.3, 147.6, 145.8, 137.8, 136.4, 132.4, 127.2, 126.6, 126.4, 125.2, 125.0, 122.9, 120.4, 119.5, 119.2, 21.6. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{15}\text{N}_2\text{O}_3$: 307.1083; found: 307.1077. FT-IR (neat, cm^{-1}) ν 3338, 2920, 1759, 1673, 1529, 1495, 1182, 724.




8-(Picolinamido)naphthalen-1-yl propionate (**3aa-2**). Following the general procedure, **3aa-2** was obtained as a colorless solid (49.9 mg, 78%). $R_f = 0.48$ (n-hexane/EtOAc 3:1). m.p. 136.0–138.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 11.51 (s, 1H), 8.77 (d, $J = 8.0$ Hz, 1H), 8.64 (d, $J = 4.4$ Hz, 1H), 8.38 (d, $J = 8.0$ Hz, 1H), 7.95 (dd, $J = 8.0, 1.6$ Hz, 1H), 7.76 (d, $J = 8.0$ Hz, 1H), 7.68 (d, $J = 8.0$ Hz, 1H), 7.55-7.50 (m, 2H), 7.46 (t, $J = 8.0$ Hz, 1H), 7.18 (dd, $J = 7.6, 1.2$ Hz, 1H), 2.84 (q, $J = 7.6$ Hz, 2H), 1.19 (t, $J = 7.6$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 173.2, 162.2, 150.3, 147.5, 126.0, 137.8, 136.4, 132.5, 127.1, 126.6, 126.4, 125.3, 125.0, 123.0, 120.3, 119.4, 119.3, 28.0, 8.9. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{17}\text{N}_2\text{O}_3$: 321.1239; found: 321.1234. FT-IR (neat, cm^{-1}) ν 3343, 2925, 1761, 1674, 1530, 1496, 1108, 748.




8-(Picolinamido)naphthalen-1-yl butyrate (**3aa-3**). Following the general procedure, **3aa-3** was obtained as a yellow solid (34.7 mg, 52%). $R_f = 0.52$ (n-hexane/EtOAc 3:1). m.p. 104.0–106.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 11.50 (s, 1H), 8.76 (d, $J = 7.6$ Hz, 1H), 8.66 (d, $J = 4.4$ Hz, 1H), 8.38 (d, $J = 8.0$ Hz, 1H), 7.95 (t, $J = 7.6$ Hz, 1H), 7.75 (d, $J = 7.6$ Hz, 1H), 7.68 (d, $J = 8.0$ Hz, 1H), 7.56-7.50 (m, 2H), 7.46 (t, $J = 7.6$ Hz, 1H), 7.17 (dd, $J = 7.6, 0.8$ Hz, 1H), 2.77 (t, $J = 7.6$ Hz, 2H), 1.77-1.67 (m, 2H), 0.92 (t, $J = 7.6$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 172.3, 162.2, 150.4, 147.6, 146.0, 137.8, 136.4, 132.5, 127.1, 126.6, 126.4, 125.3, 125.0, 123.0, 120.3,


119.4, 119.3, 36.3, 18.2, 13.5. HRMS (ESI): m/z $[M+H]^+$ calcd for $C_{20}H_{19}N_2O_3$: 335.1396; found: 335.1390. FT-IR (neat, cm^{-1}) ν 3338, 2925, 1759, 1677, 1529, 1496, 748.




8-(Picolinamido)naphthalen-1-yl isobutyrate (**3aa-4**). Following the general procedure, **3aa-4** was obtained as a yellow solid (24.7 mg, 37%). R_f = 0.52 (n-hexane/EtOAc 3:1). m.p. 100.0–102.0 °C. 1H NMR (400 MHz, $CDCl_3$) δ 11.52 (s, 1H), 8.78 (d, J = 7.6 Hz, 1H), 8.63 (d, J = 4.8 Hz, 1H), 8.38 (d, J = 7.6 Hz, 1H), 7.95 (dt, J = 7.6, 1.6 Hz, 1H), 7.75 (d, J = 8.4 Hz, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.55–7.50 (m, 2H), 7.45 (t, J = 8.0 Hz, 1H), 7.13 (dd, J = 7.6, 0.8 Hz, 1H), 3.29–3.20 (m, 1H), 1.27 (d, J = 7.2 Hz, 6H). $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 176.1, 162.3, 150.4, 147.5, 146.3, 137.8, 136.4, 132.6, 127.0, 126.5, 126.4, 125.3, 125.0, 123.0, 120.1, 119.3, 33.9, 18.8. HRMS (ESI): m/z $[M+H]^+$ calcd for $C_{20}H_{19}N_2O_3$: 335.1396; found: 335.1390. FT-IR (neat, cm^{-1}) ν 3346, 2923, 1763, 1684, 1530, 1497, 1075, 754.




8-(Picolinamido)naphthalen-1-yl pivalate (**3aa-5**). Following the general procedure, **3aa-5** was obtained as a yellow oil (45.2 mg, 65%). R_f = 0.52 (n-hexane/EtOAc 3:1). 1H NMR (400 MHz, $CDCl_3$) δ 10.72 (s, 1H), 8.66 (d, J = 4.0 Hz, 1H), 8.47 (d, J = 7.6 Hz, 1H), 8.35 (d, J = 8.0 Hz, 1H), 7.93 (dt, J = 7.6, 1.6 Hz, 1H), 7.76 (d, J = 7.6 Hz, 1H), 7.72 (d, J = 8.0 Hz, 1H), 7.55–7.48 (m, 2H), 7.45 (t, J = 7.6 Hz, 1H), 7.04 (dd, J = 7.6, 1.2 Hz, 1H), 1.26 (s, 9H). $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 178.1, 162.7, 150.3, 147.9, 147.3, 137.7, 136.4, 132.1, 127.0, 126.5, 126.3, 125.6, 125.4, 123.0, 121.0, 120.9, 120.0, 39.5, 26.9. HRMS (ESI): m/z $[M+H]^+$ calcd for $C_{21}H_{21}N_2O_3$: 349.1552; found: 349.1547. FT-IR (neat, cm^{-1}) ν 3349, 2925, 1752, 1683, 1528, 1495, 1086, 752.




8-(Picolinamido)naphthalen-1-yl nonanoate (**3aa-6**). Following the general procedure, **3aa-6** was obtained as a colorless solid (38.8 mg, 48%). R_f = 0.75 (n-hexane/EtOAc 3:1). m.p. 94.0–96.0 °C. 1H NMR (400 MHz, $CDCl_3$) δ 11.50 (s, 1H), 8.76 (dd, J = 7.6, 0.8 Hz, 1H), 8.65 (d, J = 4.8 Hz, 1H), 8.38 (d, J = 8.0 Hz, 1H), 7.95 (dt, J = 7.6, 1.6 Hz, 1H), 7.76 (dd, J = 8.0, 1.2 Hz, 1H), 7.68 (dd, J = 8.0, 1.2 Hz, 1H), 7.56–7.50 (m, 2H), 7.46 (t, J = 8.0 Hz, 1H), 7.17 (dd, J = 7.6, 0.8 Hz, 1H), 2.77 (t, J = 7.6 Hz, 2H), 1.70–1.64 (m, 2H), 1.32–1.21 (m, 10H), 0.88 (t, J = 6.8 Hz, 3H). $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 172.5, 162.2, 150.4, 147.6, 146.0, 137.8, 136.4, 132.5, 127.1, 126.5, 126.4, 125.3, 125.0, 123.0, 120.3, 119.4, 119.3, 34.5, 31.7, 29.2, 29.1, 24.7, 22.6, 14.1. HRMS (ESI): m/z $[M+H]^+$ calcd for $C_{25}H_{29}N_2O_3$: 405.2178; found: 405.2173. FT-IR (neat, cm^{-1}) ν 3361, 2922, 1766, 1683, 1529, 1496, 1091, 750.




8-(picolinamido)naphthalen-1-yl adamantane-1-carboxylate (**3aa-7**). Following the general procedure, **3aa-7** was obtained as a yellow solid (50.3 mg, 59%). $R_f = 0.52$ (n-hexane/EtOAc 3:1). m.p. 204.0–206.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 10.53 (s, 1H), 8.69 (d, $J = 4.4$ Hz, 1H), 8.36 (d, $J = 7.6$ Hz, 2H), 7.93 (dt, $J = 7.6, 1.6$ Hz, 1H), 7.78–7.68 (m, 2H), 7.55–7.47 (m, 2H), 7.44 (t, $J = 8.0$ Hz, 1H), 7.00 (dd, $J = 7.6, 1.2$ Hz, 1H), 2.10–1.96 (m, 1H), 1.94–1.86 (m, 8H), 1.66–1.60 (m, 3H), 1.52–1.46 (m, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 177.1, 162.7, 150.5, 148.0, 147.3, 137.7, 136.4, 132.0, 126.9, 126.5, 126.2, 125.8, 125.5, 123.1, 121.4, 121.2, 120.2, 41.4, 38.3, 36.2, 27.7. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{27}\text{N}_2\text{O}_3$: 427.2022; found: 427.2016. FT-IR (neat, cm^{-1}) ν 3365, 2914, 1746, 1684, 1527, 1496, 1198, 1032, 752.



8-(Picolinamido)naphthalen-1-yl cyclopropanecarboxylate (**3aa-8**). Following the general procedure, **3aa-8** was obtained as a colorless solid (39.9 mg, 60%). $R_f = 0.46$ (n-hexane/EtOAc 3:1). m.p. 148.0–150.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.55 (s, 1H), 8.68 (dd, $J = 8.0, 1.2$ Hz, 1H), 8.60 (d, $J = 4.4$ Hz, 1H), 8.38 (d, $J = 8.0$ Hz, 1H), 7.94 (dt, $J = 7.6, 1.6$ Hz, 1H), 7.76 (dd, $J = 8.0, 1.2$ Hz, 1H), 7.69 (dd, $J = 8.0, 1.2$ Hz, 1H), 7.53 (t, $J = 8.0$ Hz, 1H), 7.51–7.47 (m, 1H), 7.45 (t, $J = 8.0$ Hz, 1H), 7.19 (dd, $J = 7.6, 1.2$ Hz, 1H), 2.19–2.12 (m, 1H), 1.04–0.98 (m, 2H), 0.73–0.67 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 173.8, 162.3, 150.5, 147.6, 146.2, 137.6, 136.4, 132.4, 127.1, 126.41, 126.31, 125.5, 125.1, 122.8, 120.4, 119.8, 119.6, 13.5, 9.8. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{17}\text{N}_2\text{O}_3$: 333.1239; found: 333.1234. FT-IR (neat, cm^{-1}) ν 3357, 2923, 1752, 1683, 1530, 1498, 1125, 1086, 752.




8-(Picolinamido)naphthalen-1-yl cyclobutanecarboxylate (**3aa-9**). Following the general procedure, **3aa-9** was obtained as a colorless solid (33.2 mg, 48%). $R_f = 0.52$ (n-hexane/EtOAc 3:1). m.p. 127.0–129.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.46 (s, 1H), 8.77–8.69 (m, 2H), 8.37 (d, $J = 8.0$ Hz, 1H), 7.95 (dt, $J = 7.6, 1.6$ Hz, 1H), 7.76 (dd, $J = 8.0, 1.2$ Hz, 1H), 7.68 (dd, $J = 8.0, 1.2$ Hz, 1H), 7.57–7.50 (m, 2H), 7.46 (t, $J = 8.0$ Hz, 1H), 7.17 (dd, $J = 7.6, 1.2$ Hz, 1H), 3.81–3.70 (m, 1H), 2.43–2.32 (m, 2H), 2.18–2.08 (m, 2H), 2.00–1.92 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 174.3, 162.2, 150.5, 147.5, 146.1, 137.8, 136.4, 132.5, 127.0, 126.6, 126.4, 125.3, 125.0, 123.0, 120.2, 119.4, 119.3, 38.2, 25.3, 18.5. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{19}\text{N}_2\text{O}_3$: 347.1396; found: 347.1390. FT-IR (neat, cm^{-1}) ν 3345, 2924, 1758, 1682, 1529, 1496, 1108, 1032, 753.




3aa-10

8-(Picolinamido)naphthalen-1-yl cyclopentanecarboxylate (**3aa-10**). Following the general procedure, **3aa-10** was obtained as a yellow solid (30.2 mg, 42%). $R_f = 0.60$ (n-hexane/EtOAc 3:1). m.p. 116.0–118.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.53 (s, 1H), 8.76 (d, $J = 7.6$ Hz, 1H), 8.62 (d, $J = 3.6$ Hz, 1H), 8.38 (d, $J = 7.6$ Hz, 1H), 7.95 (t, $J = 7.6$ Hz, 1H), 7.75 (d, $J = 8.0$ Hz, 1H), 7.68 (d, $J = 8.0$ Hz, 1H), 7.57–7.49 (m, 2H), 7.45 (t, $J = 8.0$ Hz, 1H), 7.15 (d, $J = 7.6$ Hz, 1H), 3.46–3.35 (m, 1H), 1.94–1.82 (m, 4H), 1.79–1.71 (m, 2H), 1.61–1.53 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 175.7, 162.2, 150.5, 147.4, 146.2, 137.8, 136.4, 132.6, 127.0, 126.5, 126.4, 125.3, 125.0, 123.0, 120.2, 119.4, 119.3, 43.8, 30.2, 25.8. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{21}\text{N}_2\text{O}_3$: 361.1552; found: 361.1547. FT-IR (neat, cm^{-1}) ν 3339, 2928, 1760, 1682, 1529, 1496, 1105, 752.




3aa-11

8-(Picolinamido)naphthalen-1-yl cyclohexanecarboxylate (**3aa-11**). Following the general procedure, **3aa-11** was obtained as a colorless solid (56.1 mg, 75%). $R_f = 0.65$ (n-hexane/EtOAc 3:1). m.p. 148.0–150.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.42 (s, 1H), 8.74–8.67 (m, 2H), 8.38 (d, $J = 8.0$ Hz, 1H), 7.96 (dt, $J = 8.0, 1.6$ Hz, 1H), 7.75 (d, $J = 8.0$ Hz, 1H), 7.69 (d, $J = 8.0$ Hz, 1H), 7.56–7.50 (m, 2H), 7.45 (t, $J = 7.6$ Hz, 1H), 7.10 (dd, $J = 7.6, 1.2$ Hz, 1H), 2.95–2.86 (m, 1H), 1.97–1.90 (m, 2H), 1.83–1.68 (m, 3H), 1.66–1.61 (m, 1H), 1.59–1.50 (m, 2H), 1.20–1.12 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 175.0, 162.2, 150.5, 147.7, 146.3, 137.8, 136.4, 132.5, 127.0, 126.5, 126.4, 125.3, 125.1, 123.0, 120.2, 119.6, 119.5, 42.7, 28.8, 25.6, 25.3. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{23}\text{N}_2\text{O}_3$: 375.1709; found: 375.1703. FT-IR (neat, cm^{-1}) ν 3344, 2928, 1761, 1684, 1531, 1497, 1106, 1023, 751.




3aa-12


8-(Picolinamido)naphthalen-1-yl 2-(naphthalen-2-yl)acetate (**3aa-12**). Following the general procedure, **3aa-12** was obtained as a colorless solid (78.6 mg, 91%). $R_f = 0.48$ (n-hexane/EtOAc 3:1). m.p. 178.0–180.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.67 (s, 1H), 8.81 (dd, $J = 8.0, 1.2$ Hz, 1H), 8.68 (d, $J = 4.4$ Hz, 1H), 8.42 (d, $J = 7.6$ Hz, 1H), 8.10–8.04 (m, 1H), 7.93 (dt, $J = 7.6, 1.6$ Hz, 1H), 7.90–7.85 (m, 1H), 7.82 (d, $J = 8.0$ Hz, 1H), 7.73 (d, $J = 7.6$ Hz, 1H), 7.69 (d, $J = 8.0$ Hz, 1H), 7.58–7.41 (m, 6H), 7.36 (t, $J = 8.0$ Hz, 1H), 6.99 (dd, $J = 7.6, 1.2$ Hz, 1H), 4.58 (s, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 170.2, 162.3, 150.4, 147.7, 146.0, 137.9, 136.4, 133.9, 132.4, 132.0, 129.7, 128.8, 128.4, 127.9, 127.2, 126.7, 126.6, 126.5, 125.9, 125.5, 125.2, 125.1, 123.6, 123.1, 120.2, 119.6, 119.2, 39.1. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{28}\text{H}_{21}\text{N}_2\text{O}_3$: 433.1552; found: 433.1547. FT-IR (neat, cm^{-1}) ν 3349, 2923, 1766, 1682, 1530, 1497, 1101, 753.




8-(Picolinamido)naphthalen-1-yl 2,2,3,3-tetramethylcyclopropane-1-carboxylate (**3aa-13**). Following the general procedure, **3aa-13** was obtained as a white solid (38.1 mg, 49%). $R_f = 0.70$ (n-hexane/EtOAc 3:1). m.p. 172.0–174.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.70 (s, 1H), 8.77 (d, $J = 7.2$ Hz, 1H), 8.67 (d, $J = 4.8$ Hz, 1H), 8.40 (d, $J = 8.0$ Hz, 1H), 7.93 (dt, $J = 8.0, 1.6$ Hz, 1H), 7.74 (d, $J = 8.0$ Hz, 1H), 7.66 (d, $J = 7.6$ Hz, 1H), 7.54–7.43 (m, 3H), 7.18 (dd, $J = 7.6, 0.8$ Hz, 1H), 1.79 (s, 1H), 1.16 (s, 6H), 0.90 (s, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 170.1, 162.0, 150.5, 147.9, 145.9, 137.7, 136.3, 132.8, 126.7, 126.4, 126.3, 125.2, 124.7, 122.9, 121.0, 119.5, 118.6, 35.2, 32.0, 22.9, 16.3. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{25}\text{N}_2\text{O}_3$: 389.1865; found: 389.1860. FT-IR (neat, cm^{-1}) ν 3336, 2923, 1750, 1685, 1533, 1499, 1098, 1030, 752.



8-(picolinamido)naphthalen-1-yl 3-(2-bromophenyl)propanoate (**3aa-14**). Following the general procedure, **3aa-14** was obtained as a white solid (59.9 mg, 63%). $R_f = 0.50$ (n-hexane/EtOAc 3:1). m.p. 124.0–126.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.48 (s, 1H), 8.78 (d, $J = 7.6$ Hz, 1H), 8.46 (d, $J = 4.4$ Hz, 1H), 8.34 (d, $J = 8.0$ Hz, 1H), 7.91 (t, $J = 7.2$ Hz, 1H), 7.76 (d, $J = 8.0$ Hz, 1H), 7.68 (d, $J = 8.4$ Hz, 1H), 7.57–7.49 (m, 2H), 7.47–7.38 (m, 2H), 7.24–7.14 (m, 2H), 7.13–7.07 (m, 2H), 3.19–3.09 (m, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 171.4, 162.2, 150.2, 147.7, 145.8, 139.3, 137.7, 136.4, 132.9, 132.5, 130.5, 128.3, 127.6, 127.2, 126.51, 126.45, 125.2, 125.0, 124.3, 122.9, 120.3, 119.4, 119.1, 34.3, 31.0. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{20}\text{BrN}_2\text{O}_3$: 475.0657; found: 475.0652. FT-IR (neat, cm^{-1}) ν 3344, 2921, 1765, 1682, 1529, 1496, 1100, 750.




8-(Picolinamido)naphthalen-1-yl 2-methylbenzoate (**3ab-1**). Following the general procedure, **3ab-1** was obtained as a yellow solid (64.9 mg, 85%). $R_f = 0.50$ (n-hexane/EtOAc 3:1). m.p. 128.0–130.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.43 (s, 1H), 8.66 (d, $J = 7.6$ Hz, 1H), 8.26 (dd, $J = 7.6, 0.8$ Hz, 1H), 8.16 (d, $J = 7.6$ Hz, 1H), 7.81 (d, $J = 8.0$ Hz, 1H), 7.75–7.68 (m, 2H), 7.56 (t, $J = 8.0$ Hz, 1H), 7.50 (t, $J = 8.0$ Hz, 1H), 7.43 (dt, $J = 7.6, 1.2$ Hz, 1H), 7.30–7.22 (m, 3H), 7.18 (d, $J = 7.6$ Hz, 1H), 7.13–7.07 (m, 1H), 2.47 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 166.3, 162.4, 149.6, 147.1, 146.9, 141.7, 137.1, 136.5, 132.7, 132.4, 131.8, 131.7, 129.0, 127.3, 126.5, 125.81, 125.80, 125.5, 125.2, 122.0, 120.2, 120.1, 120.0, 21.6. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{19}\text{N}_2\text{O}_3$: 383.1396; found: 383.1390. FT-IR (neat, cm^{-1}) ν 3334, 2922, 1741, 1685, 1531, 1497, 1218, 1031, 737.




3ab-2

8-(Picolinamido)naphthalen-1-yl 2-methoxybenzoate (**3ab-2**). Following the general procedure, **3ab-2** was obtained as a yellow solid (39.8 mg, 50%). $R_f = 0.20$ (n-hexane/EtOAc 3:1). m.p. 144.0–146.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.54 (s, 1H), 8.69 (d, $J = 7.6$ Hz, 1H), 8.18 (d, $J = 7.6$ Hz, 1H), 8.06 (dd, $J = 7.6, 1.6$ Hz, 1H), 7.78 (d, $J = 8.0$ Hz, 1H), 7.75–7.68 (m, 2H), 7.55 (t, $J = 8.0$ Hz, 1H), 7.52–7.45 (m, 2H), 7.38 (d, $J = 7.6$ Hz, 1H), 7.29 (d, $J = 7.2$ Hz, 1H), 7.15–7.08 (m, 1H), 6.98 (t, $J = 7.6$ Hz, 1H), 6.87 (d, $J = 8.4$ Hz, 1H), 3.72 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 164.7, 162.4, 159.9, 149.8, 147.2, 146.9, 137.0, 136.4, 134.3, 132.7, 132.6, 127.0, 126.4, 125.7, 125.4, 125.0, 122.0, 120.0, 119.9, 119.7, 119.5, 111.9, 55.8. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{19}\text{N}_2\text{O}_4$: 399.1345; found: 399.1339. FT-IR (neat, cm^{-1}) ν 3336, 2925, 1750, 1684, 1531, 1495, 1214, 1025, 754.




3ab-3

8-(Picolinamido)naphthalen-1-yl 2-acetylbenzoate (**3ab-3**). Following the general procedure, **3ab-3** was obtained as a yellow solid (50.0 mg, 61%). $R_f = 0.20$ (n-hexane/EtOAc 3:1). m.p. 176.0–178.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.02 (s, 1H), 8.46 (d, $J = 7.6$ Hz, 1H), 8.25 (d, $J = 8.0$ Hz, 2H), 8.14 (d, $J = 6.8$ Hz, 1H), 7.91 (d, $J = 8.0$ Hz, 2H), 7.83 (d, $J = 7.6$ Hz, 1H), 7.77 (d, $J = 8.4$ Hz, 1H), 7.69 (t, $J = 6.0$ Hz, 1H), 7.56 (t, $J = 7.6$ Hz, 1H), 7.49 (t, $J = 7.6$ Hz, 1H), 7.44 (d, $J = 4.0$ Hz, 1H), 7.24 (d, $J = 7.2$ Hz, 1H), 7.15–7.03 (m, 1H), 2.64 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 197.3, 164.9, 162.4, 149.5, 147.0, 146.5, 140.4, 137.2, 136.5, 133.4, 131.8, 130.8, 128.0, 127.6, 126.5, 125.9, 125.8, 125.5, 122.3, 121.4, 120.6, 120.1, 26.9. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{19}\text{N}_2\text{O}_4$: 411.1345; found: 411.1339. FT-IR (neat, cm^{-1}) ν 3351, 2922, 1742, 1685, 1529, 1496, 1226, 1055, 754.




3ab-5

8-(picolinamido)naphthalen-1-yl 3-methylbenzoate (**3ab-5**). Following the general procedure, **3ab-5** was obtained as a yellow solid (63.1 mg, 71%). $R_f = 0.50$ (n-hexane/EtOAc 3:1). m.p. 156.0–158.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.31 (s, 1H), 8.59 (d, $J = 7.6$ Hz, 1H), 8.17 (d, $J = 7.6$ Hz, 1H), 8.04 (d, $J = 7.6$ Hz, 1H), 8.00 (s, 1H), 7.81 (d, $J = 8.0$ Hz, 1H), 7.77–7.69 (m, 2H), 7.56 (t, $J = 8.0$ Hz, 1H), 7.49 (t, $J = 8.0$ Hz, 1H), 7.40 (d, $J = 7.6$ Hz, 1H), 7.35–7.30 (m, 2H), 7.23 (dd, $J = 7.6, 0.4$ Hz, 1H), 7.15–7.09 (m, 1H), 2.37 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 166.1, 162.6, 149.7, 147.2, 147.1, 138.2, 137.0, 136.5, 134.3, 132.3, 131.2, 129.8, 128.3, 128.0, 127.3, 126.5, 125.8, 125.5, 125.4, 122.1, 120.5, 120.4, 120.1, 21.2. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{19}\text{N}_2\text{O}_3$: 383.1396; found: 383.1390. FT-IR (neat, cm^{-1}) ν 3344, 2920, 1739, 1684, 1530, 1496, 1260, 1177, 1050, 748.




3ab-6

8-(Picolinamido)naphthalen-1-yl 3-methoxybenzoate (**3ab-6**). Following the general procedure, **3ab-6** was obtained as a yellow solid (50.9 mg, 64%). $R_f = 0.30$ (n-hexane/EtOAc 3:1). m.p. 142.0–144.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.26 (s, 1H), 8.57 (d, $J = 7.6$ Hz, 1H), 8.16 (d, $J = 7.6$ Hz, 1H), 7.84 (d, $J = 7.6$ Hz, 1H), 7.81 (d, $J = 8.0$ Hz, 1H), 7.77–7.65 (m, 3H), 7.56 (t, $J = 7.6$ Hz, 1H), 7.49 (t, $J = 7.6$ Hz, 1H), 7.44 (d, $J = 4.4$ Hz, 1H), 7.33 (t, $J = 8.0$ Hz, 1H), 7.23 (dd, $J = 7.6, 0.8$ Hz, 1H), 7.16–7.08 (m, 2H), 3.80 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 165.7, 162.5, 159.4, 149.6, 147.2, 146.9, 137.0, 136.4, 132.2, 131.0, 129.3, 127.3, 126.5, 125.9, 125.5, 125.4, 123.2, 122.1, 120.7, 120.4, 120.3, 120.0, 114.7, 55.4. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{19}\text{N}_2\text{O}_4$: 399.1345; found: 399.1339. FT-IR (neat, cm^{-1}) ν 3351, 2916, 1737, 1683, 1529, 1492, 1263, 1206, 1032, 748.




3ab-7

8-(Picolinamido)naphthalen-1-yl 3-acetylbenzoate (**3ab-7**). Following the general procedure, **3ab-7** was obtained as a yellow solid (49.2 mg, 60%). $R_f = 0.20$ (n-hexane/EtOAc 3:1). m.p. 147.0–149.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.00 (s, 1H), 8.67 (s, 1H), 8.43 (d, $J = 7.6$ Hz, 1H), 8.38 (d, $J = 7.6$ Hz, 1H), 8.16–8.10 (m, 2H), 7.83 (d, $J = 8.0$ Hz, 1H), 7.76 (d, $J = 7.6$ Hz, 1H), 7.67 (dt, $J = 7.6, 1.2$ Hz, 1H), 7.56 (t, $J = 7.6$ Hz, 1H), 7.50 (dt, $J = 7.6, 2.4$ Hz, 2H), 7.40 (d, $J = 4.4$ Hz, 1H), 7.24 (dd, $J = 7.6, 0.8$ Hz, 1H), 7.08 (dd, $J = 7.6, 4.4$ Hz, 1H), 2.59 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 196.9, 164.9, 162.3, 149.4, 147.0, 146.5, 137.1, 136.4, 134.8, 132.6, 131.7, 130.5, 130.2, 128.8, 127.5, 126.5, 125.9, 125.8, 125.5, 122.2, 121.6, 120.7, 120.1, 26.7. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{19}\text{N}_2\text{O}_4$: 411.1345; found: 411.1339. FT-IR (neat, cm^{-1}) ν 3344, 2920, 1743, 1686, 1529, 1496, 1211, 749.




3ab-8

8-(Picolinamido)naphthalen-1-yl 3-cyanobenzoate (**3ab-8**). Following the general procedure, **3ab-8** was obtained as a yellow solid (35.4 mg, 45%). $R_f = 0.20$ (n-hexane/EtOAc 3:1). m.p. 176.0–178.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 10.8 (s, 1H), 8.45 (s, 1H), 8.35 (dt, $J = 8.8, 1.6$ Hz, 1H), 8.31 (d, $J = 7.6$ Hz, 1H), 8.17 (d, $J = 8.0$ Hz, 1H), 7.86 (dd, $J = 8.4, 1.2$ Hz, 1H), 7.82–7.74 (m, 3H), 7.72 (d, $J = 4.8$ Hz, 1H), 7.57 (t, $J = 8.0$ Hz, 1H), 7.53–7.46 (m, 2H), 7.25–7.20 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 163.8, 162.4, 149.5, 147.2, 146.2, 137.4, 136.5, 136.3, 134.5, 134.0, 131.4, 130.9, 129.3, 127.9, 126.6, 126.21, 126.18, 125.5, 122.5, 122.3, 121.0, 120.1, 117.5, 112.8. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{16}\text{N}_3\text{O}_3$: 394.1192; found: 394.1186. FT-IR (neat, cm^{-1}) ν 3362, 2918, 1745, 1684, 1529, 1495, 1258, 1166, 749.




3ab-9

8-(Picolinamido)naphthalen-1-yl benzoate (**3ab-9**). Following the general procedure, **3ab-9** was obtained as a yellow solid (62.6 mg, 85%). m.p. 148.0–150.0 °C. $R_f = 0.38$ (n-hexane/EtOAc 3:1). ^1H NMR (400 MHz, CDCl_3) δ 11.34 (s, 1H), 8.63 (d, $J = 7.6$ Hz, 1H), 8.23 (d, $J = 7.2$ Hz, 2H), 8.16 (d, $J = 7.6$ Hz, 1H), 7.81 (d, $J = 8.0$ Hz, 1H), 7.76–7.67 (m, 2H), 7.63–7.54 (m, 2H), 7.49 (t, $J = 8.0$ Hz, 1H), 7.44 (t, $J = 8.0$ Hz, 2H), 7.31 (t, $J = 4.4$ Hz, 1H), 7.23 (dd, $J = 7.6, 0.8$ Hz, 1H), 7.13–7.08 (m, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 165.9, 162.5, 149.6, 147.2, 147.0, 137.1, 136.5, 133.5, 132.3, 130.7, 129.9, 128.4, 127.3, 126.5, 125.8, 125.5, 125.4, 122.1, 120.4, 120.3, 120.0. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{17}\text{N}_2\text{O}_3$: 369.1239; found: 369.1234. FT-IR (neat, cm^{-1}) ν 3345, 2921, 1740, 1683, 1529, 1495, 1220, 1049, 752.




3ab-10

8-(Picolinamido)naphthalen-1-yl 4-methylbenzoate (**3ab-10**). Following the general procedure, **3ab-10** was obtained as a yellow solid (71.8 mg, 94%). $R_f = 0.38$ (n-hexane/EtOAc 3:1). m.p. 159.0–161.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 11.33 (s, 1H), 8.62 (d, $J = 7.6$ Hz, 1H), 8.15 (d, $J = 7.6$ Hz, 1H), 8.10 (d, $J = 7.6$ Hz, 2H), 7.80 (d, $J = 8.4$ Hz, 1H), 7.75–7.68 (m, 2H), 7.56 (t, $J = 8.0$ Hz, 1H), 7.48 (t, $J = 8.0$ Hz, 1H), 7.37 (d, $J = 4.4$ Hz, 1H), 7.24–7.18 (m, 3H), 7.15–7.09 (m, 1H), 2.43 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 165.6, 162.5, 149.6, 147.2, 147.0, 144.3, 137.0, 136.4, 132.3, 130.8, 129.0, 127.2, 127.1, 126.4, 125.6, 125.5, 125.3, 122.1, 120.31, 120.29, 120.0, 21.7. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{19}\text{N}_2\text{O}_3$: 383.1396; found: 383.1390. FT-IR (neat, cm^{-1}) ν 3345, 2920, 1737, 1683, 1529, 1496, 1219, 1049, 748.




3ab-11


8-(Picolinamido)naphthalen-1-yl 4-methoxybenzoate (**3ab-11**). Following the general procedure, **3ab-11** was obtained as a white solid (54.1 mg, 68%). $R_f = 0.50$ (n-hexane/EtOAc 3:1). m.p. 209.0–211.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 11.36 (s, 1H), 8.59 (dd, $J = 7.6, 0.8$ Hz, 1H), 8.22–8.14 (m, 3H), 7.80 (dd, $J = 8.4, 1.2$ Hz, 1H), 7.77–7.72 (m, 2H), 7.56 (t, $J = 8.0$ Hz, 1H), 7.52–7.46 (m, 2H), 7.22 (dd, $J = 7.6, 1.2$ Hz, 1H), 7.20–7.15 (m, 1H), 6.92–6.86 (m, 2H), 3.90 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 165.6, 163.8, 162.4, 149.7, 147.2, 147.1, 137.3, 136.5, 133.0, 132.3, 127.1, 126.5, 125.8, 125.5, 125.4, 122.3, 122.2, 120.5, 120.4, 120.1, 113.6, 55.6. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{19}\text{N}_2\text{O}_4$: 399.1345; found: 399.1339. FT-IR (neat, cm^{-1}) ν 3337, 2922, 1731, 1680, 1527, 1496, 1247, 1028, 754.




8-(Picolinamido)naphthalen-1-yl 4-phenoxybenzoate (**3ab-12**). Following the general procedure, **3ab-12** was obtained as a white solid (88.3 mg, 96%). $R_f = 0.38$ (n-hexane/EtOAc 3:1). m.p. 137.0–139.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.31 (s, 1H), 8.62 (dd, $J = 8.0, 1.2$ Hz, 1H), 8.24–8.17 (m, 3H), 7.84–7.74 (m, 3H), 7.65–7.61 (m, 1H), 7.58 (t, $J = 8.0$ Hz, 1H), 7.53–7.43 (m, 3H), 7.29–7.22 (m, 3H), 7.13–7.07 (m, 2H), 7.00–7.95 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 165.2, 162.4, 162.2, 155.3, 149.7, 147.2, 146.9, 137.1, 136.4, 132.9, 132.2, 130.1, 127.2, 126.4, 125.8, 125.5, 125.4, 124.7, 123.8, 122.2, 120.5, 120.3, 120.1, 120.0, 117.1. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{29}\text{H}_{21}\text{N}_2\text{O}_4$: 461.1501; found: 461.1496. FT-IR (neat, cm^{-1}) ν 3344, 2922, 1737, 1684, 1530, 1494, 1240, 1048, 751.




8-(Picolinamido)naphthalen-1-yl 4-acetylbenzoate (**3ab-13**). Following the general procedure, **3ab-13** was obtained as a yellow solid (25.4 mg, 31%). $R_f = 0.20$ (n-hexane/EtOAc 3:1). m.p. 173.0–175.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.01 (s, 1H), 8.46 (d, $J = 8.0$ Hz, 1H), 8.26 (d, $J = 8.0$ Hz, 2H), 8.14 (d, $J = 8.0$ Hz, 1H), 7.93 (d, $J = 8.0$ Hz, 2H), 7.84 (d, $J = 8.0$ Hz, 1H), 7.78 (d, $J = 8.0$ Hz, 1H), 7.71 (t, $J = 7.2$ Hz, 1H), 7.57 (t, $J = 8.0$ Hz, 1H), 7.51 (t, $J = 8.0$ Hz, 1H), 7.46 (d, $J = 4.8$ Hz, 1H), 7.25 (d, $J = 8.0$ Hz, 1H), 7.13–7.07 (m, 1H), 2.65 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 197.3, 164.9, 162.5, 149.6, 147.1, 146.6, 140.5, 137.2, 136.5, 133.4, 131.8, 130.9, 128.0, 127.6, 126.6, 125.9, 125.8, 125.5, 122.3, 121.5, 120.6, 120.1, 26.9. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{19}\text{N}_2\text{O}_4$: 411.1345; found: 411.1339. FT-IR (neat, cm^{-1}) ν 3355, 2917, 1741, 1684, 1529, 1496, 1228, 1053, 754.




8-(Picolinamido)naphthalen-1-yl 4-chlorobenzoate (**3ab-14**). Following the general procedure, **3ab-14** was obtained as a yellow solid (70.8 mg, 88%). $R_f = 0.48$ (n-hexane/EtOAc 3:1). m.p. 143.0–145.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.00 (s, 1H), 8.45 (d, $J = 7.6$ Hz, 1H), 8.16 (d, $J = 7.6$ Hz, 1H), 8.09 (d, $J = 7.6$ Hz, 2H), 7.82 (d, $J = 8.4$ Hz, 1H), 7.78–7.71 (m, 2H), 7.59–7.53 (m, 2H), 7.48 (t, $J = 7.6$ Hz, 1H), 7.32 (d, $J = 7.6$ Hz, 2H), 7.24–7.18 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 146.9, 162.4, 149.5, 147.1, 146.6, 139.9, 137.2, 136.4, 131.9, 131.8, 128.6, 128.1, 127.5, 126.5, 125.9, 125.8, 125.5, 122.3, 121.5, 120.7, 120.1. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{16}\text{ClN}_2\text{O}_3$: 403.0849; found: 403.0844. FT-IR (neat, cm^{-1}) ν 3349, 2926, 1740, 1683, 1528, 1492, 1219, 1051, 750.




8-(Picolinamido)naphthalen-1-yl 4-cyanobenzoate (**3ab-15**). Following the general procedure, **3ab-15** was obtained as a white solid (55.0 mg, 70%). $R_f = 0.25$ (n-hexane/EtOAc 3:1). m.p. 163.0–165.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 10.78 (s, 1H), 8.35 (d, $J = 7.2$ Hz, 1H), 8.25 (d, $J = 8.0$ Hz, 2H), 8.15 (d, $J = 7.2$ Hz, 1H), 7.85 (d, $J = 7.6$ Hz, 1H), 7.82–7.72 (m, 2H), 7.63 (d, $J = 8.0$ Hz, 2H), 7.60–7.54 (m, 2H), 7.51 (t, $J = 8.0$ Hz, 1H), 7.25–7.19 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 164.1, 162.4, 149.5, 147.0, 146.2, 137.4, 136.5, 133.4, 132.0, 131.4, 131.0, 127.9, 126.6, 126.2, 126.1, 125.5, 122.5, 122.3, 120.8, 120.1, 117.7, 116.7. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{16}\text{N}_3\text{O}_3$: 394.1192; found: 394.1186. FT-IR (neat, cm^{-1}) ν 3352, 2921, 1745, 1685, 1530, 1496, 1251, 1222, 1061, 754.



8-(Picolinamido)naphthalen-1-yl 4-(trifluoromethyl)benzoate (**3ab-16**). Following the general procedure, **3ab-16** was obtained as a yellow solid (49.7 mg, 57%). $R_f = 0.52$ (n-hexane/EtOAc 3:1). m.p. 150.0–152.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 10.80 (s, 1H), 8.33 (d, $J = 7.6$ Hz, 1H), 8.24 (d, $J = 8.0$ Hz, 2H), 8.13 (d, $J = 8.0$ Hz, 1H), 7.85 (d, $J = 8.0$ Hz, 1H), 7.79 (d, $J = 8.0$ Hz, 1H), 7.71 (dt, $J = 7.6, 1.6$ Hz, 1H), 7.61–7.48 (m, 5H), 7.25 (dd, $J = 7.6, 0.8$ Hz, 1H), 7.17–7.11 (m, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 164.5, 162.5, 149.5, 147.1, 146.4, 137.3, 136.6, 134.7 (q, $J_{\text{C-F}} = 32.6$ Hz), 132.9, 131.6, 130.9, 127.8, 126.6, 126.2, 126.1, 125.3, 125.2 (q, $J_{\text{C-F}} = 3.7$ Hz), 123.5 (q, $J_{\text{C-F}} = 271.1$ Hz), 122.4, 121.0, 120.2. ^{19}F NMR (376 MHz, CDCl_3) δ -63.2. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{16}\text{F}_3\text{N}_2\text{O}_3$: 437.1113; found: 437.1108. FT-IR (neat, cm^{-1}) ν 3345, 2920, 1744, 1684, 1528, 1494, 1321, 1063, 752.




8-(Picolinamido)naphthalen-1-yl 4-nitrobenzoate (**3ab-17**). Following the general procedure, **3ab-17** was obtained as a yellow solid (57.8 mg, 70%). $R_f = 0.28$ (n-hexane/EtOAc 3:1). m.p. 187.0–189.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 10.72 (s, 1H), 8.30 (d, $J = 8.8$ Hz, 3H), 8.13 (d, $J = 8.8$ Hz, 3H), 7.86 (dd, $J = 8.0, 1.2$ Hz, 1H), 7.80 (dd, $J = 8.0, 1.2$ Hz, 1H), 7.72 (dt, $J = 7.6, 1.6$ Hz, 1H), 7.63–7.60 (m, 1H), 7.57 (t, $J = 8.0$ Hz, 1H), 7.52 (t, $J = 8.0$ Hz, 1H), 7.25 (dd, $J = 7.6, 1.2$ Hz, 1H), 7.18–7.13 (m, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 163.8, 162.4, 150.5, 149.5, 147.0, 146.1, 137.4, 136.5, 134.9, 131.6, 131.3, 127.9, 126.6, 126.3, 126.1, 125.5, 123.2, 122.6, 122.5, 120.9, 120.1. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{16}\text{N}_3\text{O}_5$: 414.1090; found: 414.1084. FT-IR (neat, cm^{-1}) ν 3342, 2923, 1742, 1673, 1523, 1496, 1240, 1063, 753.




3ab-18

8-(Picolinamido)naphthalen-1-yl furan-2-carboxylate (**3ab-18**). Following the general procedure, **3ab-18** was obtained as a white solid (40.1 mg, 56%). $R_f = 0.25$ (n-hexane/EtOAc 3:1). m.p. 167.0–169.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.19 (s, 1H), 8.51 (d, $J = 7.6$ Hz, 1H), 8.22 (d, $J = 8.0$ Hz, 1H), 7.92 (d, $J = 4.0$ Hz, 1H), 7.83–7.72 (m, 3H), 7.59–7.52 (m, 2H), 7.48 (t, $J = 7.6$ Hz, 1H), 7.37 (d, $J = 7.6$ Hz, 1H), 7.29–7.21 (m, 2H), 6.50–6.42 (m, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 162.5, 157.2, 149.8, 147.4, 147.1, 146.0, 144.2, 137.3, 136.4, 132.0, 127.5, 126.5, 125.9, 125.6, 125.4, 122.3, 121.1, 120.4, 120.2, 120.0, 112.2. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{15}\text{N}_2\text{O}_4$: 359.1032; found: 359.1026. FT-IR (neat, cm^{-1}) ν 3347, 2921, 1741, 1683, 1530, 1496, 1066, 753.




3ab-20

8-(Picolinamido)naphthalen-1-yl thiophene-2-carboxylate (**3ab-20**). Following the general procedure, **3ab-20** was obtained as a white solid (66.6 mg, 89%). $R_f = 0.30$ (n-hexane/EtOAc 3:1). m.p. 180.0–182.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.34 (s, 1H), 8.62 (d, $J = 7.6$ Hz, 1H), 8.20 (d, $J = 7.6$ Hz, 1H), 8.00 (d, $J = 3.6$ Hz, 1H), 7.82 (d, $J = 8.0$ Hz, 1H), 7.78–7.72 (m, 2H), 7.63 (d, $J = 4.4$ Hz, 2H), 7.58 (t, $J = 7.6$ Hz, 1H), 7.49 (t, $J = 7.6$ Hz, 1H), 7.29–7.24 (m, 1H), 7.22–7.17 (m, 1H), 7.10 (t, $J = 4.4$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 162.5, 161.1, 149.6, 147.1, 146.5, 137.1, 136.4, 135.2, 133.9, 133.3, 132.1, 127.8, 127.4, 126.4, 125.9, 125.40, 125.36, 122.1, 120.6, 120.3, 120.0. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{15}\text{N}_2\text{O}_3\text{S}$: 375.0803; found: 375.0798. FT-IR (neat, cm^{-1}) ν 3333, 2917, 1717, 1679, 1490, 1420, 1252, 1218, 736.




3ab-22

8-(Picolinamido)naphthalen-1-yl furan-3-carboxylate (**3ab-22**). Following the general procedure, **3ab-22** was obtained as a white solid (55.5 mg, 72%). $R_f = 0.30$ (n-hexane/EtOAc 3:1). m.p. 147.0–149.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.25 (s, 1H), 8.60 (d, $J = 8.0$ Hz, 1H), 8.30–8.21 (m, 2H), 7.95 (d, $J = 4.4$ Hz, 1H), 7.84–7.78 (m, 2H), 7.75 (d, $J = 7.8$ Hz, 1H), 7.58 (t, $J = 8.0$ Hz, 1H), 7.50 (t, $J = 8.0$ Hz, 1H), 7.42 (t, $J = 1.6$ Hz, 1H), 7.35–7.30 (m, 1H), 7.24 (dd, $J = 7.8, 0.8$ Hz, 1H), 6.85 (d, $J = 1.6$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 162.5, 161.7, 149.8, 149.5, 147.2, 146.2, 143.6, 137.3, 136.4, 132.1, 127.3, 126.4, 126.1, 125.5, 125.4, 122.4, 120.7, 120.3, 120.1, 118.9, 110.4. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{15}\text{N}_2\text{O}_4$: 359.1032; found: 359.1026. FT-IR (neat, cm^{-1}) ν 3333, 2921, 1735, 1680, 1491, 1428, 1114, 750.




3ab-24

8-(picolinamido)naphthalen-1-yl thiophene-3-carboxylate (**3ab-24**). Following the general procedure, **3ab-24** was obtained as a white solid (68.1 mg, 91%). $R_f = 0.30$ (n-hexane/EtOAc 3:1). m.p. 162.0–164.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.29 (s, 1H), 8.58 (d, $J = 7.8$ Hz, 1H), 8.32 (d, $J = 1.6$ Hz, 1H), 8.18 (d, $J = 8.0$ Hz, 1H), 7.82–7.71 (m, 3H), 7.65 (t, $J = 4.4$ Hz, 2H), 7.55 (t, $J = 8.0$ Hz, 1H), 7.47 (t, $J = 8.0$ Hz, 1H), 7.30–7.26 (m, 1H), 7.24–7.16 (m, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 162.5, 161.5, 149.6, 147.3, 146.6, 137.1, 136.4, 134.8, 133.0, 132.2, 128.7, 127.3, 126.4, 126.0, 125.9, 125.4, 125.3, 122.2, 120.5, 120.3, 120.0. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{15}\text{N}_2\text{O}_3\text{S}$: 375.0803; found: 375.0798. FT-IR (neat, cm^{-1}) ν 3328, 2916, 1728, 1678, 1529, 1494, 1238, 1188, 746.




3ab-29

8-(Picolinamido)naphthalen-1-yl 2-naphthoate (**3ab-29**). Following the general procedure, **3ab-29** was obtained as a white solid (62.7 mg, 75%). $R_f = 0.48$ (n-hexane/EtOAc 3:1). m.p. 191.0–193.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.16 (s, 1H), 8.76 (s, 1H), 8.48 (d, $J = 7.6$ Hz, 1H), 8.17 (d, $J = 7.6$ Hz, 1H), 8.07 (d, $J = 7.6$ Hz, 1H), 7.89 (t, $J = 7.2$ Hz, 2H), 7.83 (t, $J = 8.0$ Hz, 2H), 7.78 (d, $J = 8.0$ Hz, 1H), 7.64 (t, $J = 7.6$ Hz, 1H), 7.60–7.45 (m, 4H), 7.30 (d, $J = 7.2$ Hz, 1H), 7.09 (d, $J = 4.4$ Hz, 1H), 6.73–6.65 (m, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 166.0, 162.6, 149.4, 146.92, 146.89, 136.8, 136.5, 135.6, 132.4, 132.2, 132.0, 129.4, 128.7, 128.1, 127.7, 127.3, 126.9, 126.8, 126.4, 125.8, 125.7, 125.6, 125.4, 122.0, 121.3, 120.8, 120.2. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{19}\text{N}_2\text{O}_3$: 419.1396; found: 419.1390. FT-IR (neat, cm^{-1}) ν 3349, 2924, 1737, 1684, 1530, 1497, 1217, 1186, 755.




3ab-31


8-(Picolinamido)naphthalen-1-yl 1-naphthoate (**3ab-31**). Following the general procedure, **3ab-31** was obtained as a yellow solid (66.8 mg, 80%). $R_f = 0.48$ (n-hexane/EtOAc 3:1). m.p. 172.0–174.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.28 (s, 1H), 8.77–8.69 (m, 1H), 8.56 (d, $J = 7.6$ Hz, 1H), 8.52 (d, $J = 7.2$ Hz, 1H), 7.99 (d, $J = 8.0$ Hz, 1H), 7.90 (d, $J = 8.0$ Hz, 1H), 7.85 (d, $J = 8.0$ Hz, 1H), 7.82–7.75 (m, 2H), 7.61–7.45 (m, 5H), 7.41 (t, $J = 7.6$ Hz, 1H), 7.35 (dd, $J = 7.6, 1.2$ Hz, 1H), 6.91 (d, $J = 4.4$ Hz, 1H), 6.78–6.71 (m, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 166.1, 162.3, 149.2, 146.7, 146.5, 136.5, 136.4, 134.1, 133.5, 132.2, 131.5, 131.4, 128.22, 128.19, 127.4, 126.5, 126.4, 126.3, 125.54, 125.51, 125.4, 125.3, 124.3, 121.7, 120.7, 120.5, 120.2. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{27}\text{H}_{19}\text{N}_2\text{O}_3$: 419.1396; found: 419.1390. FT-IR (neat, cm^{-1}) ν 3343, 2917, 1735, 1684, 1530, 1497, 1108, 752.




8-(Picolinamido)naphthalen-1-yl benzo[d][1,3]dioxole-5-carboxylate (**3ab-32**). Following the general procedure, **3ab-32** was obtained as a white solid (61.8 mg, 75%). $R_f = 0.25$ (n-hexane/EtOAc 3:1). m.p. 181.0–183.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 11.6 (s, 1H), 8.51 (d, $J = 7.6$ Hz, 1H), 8.18 (d, $J = 7.6$ Hz, 1H), 7.85–7.73 (m, 5H), 7.61 (d, $J = 1.6$ Hz, 1H), 7.55 (t, $J = 8.0$ Hz, 1H), 7.48 (t, $J = 8.0$ Hz, 1H), 7.25–7.18 (m, 2H), 6.79 (d, $J = 8.0$ Hz, 1H), 6.04 (s, 2H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 165.1, 162.5, 152.0, 149.8, 147.5, 147.3, 146.9, 137.1, 136.5, 132.1, 127.2, 126.9, 126.4, 125.8, 125.6, 125.5, 123.6, 122.3, 120.9, 120.6, 120.1, 110.5, 107.9, 101.9. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{17}\text{N}_2\text{O}_5$: 413.1137; found: 413.1132. FT-IR (neat, cm^{-1}) ν 3340, 2924, 1733, 1684, 1531, 1495, 1258, 1034, 753.



8-(picolinamido)naphthalen-1-yl acrylate (**3ac-1**). Following the general procedure, **3ac-1** was obtained as a white solid (24.8 mg, 39%). $R_f = 0.48$ (n-hexane/EtOAc 3:1). m.p. 159.0–161.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 11.48 (s, 1H), 8.73 (d, $J = 7.6$ Hz, 1H), 8.61 (d, $J = 4.4$ Hz, 1H), 8.33 (d, $J = 7.6$ Hz, 1H), 7.91 (dt, $J = 7.6$, 1.6 Hz, 1H), 7.78 (d, $J = 8.0$ Hz, 1H), 7.70 (d, $J = 8.0$ Hz, 1H), 7.54 (t, $J = 8.0$ Hz, 1H), 7.51–7.44 (m, 2H), 7.23 (d, $J = 7.2$ Hz, 1H), 6.60 (d, $J = 5.2$ Hz, 1H), 6.59 (s, 1H), 5.91 (dd, $J = 7.6$, 4.0 Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 164.8, 162.3, 150.2, 147.6, 145.9, 137.6, 136.4, 132.7, 132.4, 128.0, 127.3, 126.5, 126.4, 125.3, 125.1, 122.8, 120.1, 120.0, 119.4. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{15}\text{N}_2\text{O}_3$: 319.1083; found: 319.1077. FT-IR (neat, cm^{-1}) ν 3340, 2921, 1745, 1675, 1533, 1497, 1121, 757.




8-(picolinamido)naphthalen-1-yl methacrylate (**3ac-2**). Following the general procedure, **3ac-2** was obtained as a white solid (27.9 mg, 42%). $R_f = 0.48$ (n-hexane/EtOAc 3:1). m.p. 169.0–171.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 11.21 (s, 1H), 8.60 (dd, $J = 8.0$, 1.2 Hz, 1H), 8.48 (d, $J = 4.8$ Hz, 1H), 8.30 (dt, $J = 8.0$, 1.2 Hz, 1H), 7.88 (dt, $J = 7.6$, 1.2 Hz, 1H), 7.77 (dd, $J = 8.4$, 1.2 Hz, 1H), 7.72 (dd, $J = 8.4$, 1.2 Hz, 1H), 7.54 (t, $J = 7.6$ Hz, 1H), 7.48–7.42 (m, 2H), 7.13 (dd, $J = 7.6$, 1.2 Hz, 1H), 6.42 (s, 1H), 5.70 (t, $J = 1.2$ Hz, 1H), 1.99 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 166.5, 162.4, 150.2, 147.4, 146.9, 137.5, 136.4, 135.9, 132.2, 127.9, 127.2, 126.4, 126.3, 125.4, 125.3, 122.5, 120.4, 120.3, 120.0, 18.5. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{17}\text{N}_2\text{O}_3$: 333.1239; found: 333.1234. FT-IR (neat, cm^{-1}) ν 3324, 2924, 1730, 1675, 1533, 1494, 1104, 759.




3ac-3

8-(picolinamido)naphthalen-1-yl cinnamate (**3ac-3**). Following the general procedure, **3ac-3** was obtained as a yellow solid (63.0 mg, 80%). $R_f = 0.48$ (n-hexane/EtOAc 3:1). m.p. 131.0–133.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 11.44 (s, 1H), 8.63 (d, $J = 7.6$ Hz, 1H), 8.41 (d, $J = 4.4$ Hz, 1H), 8.28 (d, $J = 7.6$ Hz, 1H), 7.83–7.70 (m, 4H), 7.55 (t, $J = 8.0$ Hz, 1H), 7.49 (t, $J = 8.0$ Hz, 1H), 7.44–7.35 (m, 5H), 7.27 (d, $J = 8.0$ Hz, 1H), 7.22–7.17 (m, 1H), 6.79 (d, $J = 15.6$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 165.6, 162.2, 150.1, 147.6, 146.9, 146.2, 137.5, 136.4, 134.0, 132.3, 130.8, 128.9, 128.2, 127.1, 126.4, 126.1, 125.4, 125.3, 122.7, 122.6, 120.2, 119.8, 117.5. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{19}\text{N}_2\text{O}_3$: 395.1396; found: 395.1390. FT-IR (neat, cm^{-1}) ν 3342, 2925, 1736, 1683, 1530, 1496, 1113, 753.




3ac-4

8-(picolinamido)naphthalen-1-yl 3-(p-tolyl)acrylate (**3ac-4**). Following the general procedure, **3ac-4** was obtained as a white solid (67.7 mg, 83%). $R_f = 0.60$ (n-hexane/EtOAc 3:1). m.p. 171.0–173.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 11.49 (s, 1H), 8.66 (d, $J = 7.6$ Hz, 1H), 8.41 (d, $J = 4.4$ Hz, 1H), 8.26 (d, $J = 8.0$ Hz, 1H), 7.82–7.73 (m, 3H), 7.69 (d, $J = 8.4$ Hz, 1H), 7.53 (t, $J = 8.0$ Hz, 1H), 7.47 (t, $J = 8.0$ Hz, 1H), 7.32 (d, $J = 8.0$ Hz, 2H), 7.27–7.21 (m, 2H), 7.18 (d, $J = 8.0$ Hz, 2H), 6.75 (d, $J = 16.0$ Hz, 1H), 2.39 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 165.8, 162.3, 150.2, 147.7, 147.0, 146.3, 141.4, 137.5, 136.4, 132.4, 131.3, 129.6, 128.3, 127.0, 126.4, 126.1, 125.4, 125.2, 122.7, 120.2, 119.9, 119.7, 116.4, 21.5. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{26}\text{H}_{21}\text{N}_2\text{O}_3$: 409.1552; found: 409.1547. FT-IR (neat, cm^{-1}) ν 3343, 2925, 1737, 1684, 1531, 1498, 1110, 753.




3ac-5

8-(picolinamido)naphthalen-1-yl 3-(4-methoxyphenyl)acrylate (**3ac-5**). Following the general procedure, **3ac-5** was obtained as a yellow solid (67.8 mg, 80%). $R_f = 0.30$ (n-hexane/EtOAc 3:1). m.p. 149.0–151.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 11.51 (s, 1H), 8.67 (d, $J = 8.0$ Hz, 1H), 8.42 (d, $J = 4.8$ Hz, 1H), 8.27 (d, $J = 7.6$ Hz, 1H), 7.81–7.73 (m, 3H), 7.70 (d, $J = 8.0$ Hz, 1H), 7.54 (t, $J = 8.0$ Hz, 1H), 7.48 (t, $J = 8.0$ Hz, 1H), 7.39 (d, $J = 8.4$ Hz, 2H), 7.27–7.21 (m, 2H), 6.90 (d, $J = 8.4$ Hz, 2H), 6.66 (d, $J = 15.6$ Hz, 1H), 3.86 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 165.9, 162.3, 161.8, 150.2, 147.7, 146.6, 146.3, 137.4, 136.4, 132.4, 130.0, 127.0, 126.7, 126.4, 126.1, 125.4, 125.1, 122.6, 120.2, 119.9, 119.7, 114.9, 114.3, 55.4. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{26}\text{H}_{21}\text{N}_2\text{O}_4$: 425.1501; found: 425.1496. FT-IR (neat, cm^{-1}) ν 3341, 2927, 1735, 1684, 1600, 1532, 1510, 1108, 757.



8-(picolinamido)naphthalen-1-yl


3-(4-(trifluoromethyl)phenyl)acrylate (**3ac-6**). Following the general procedure, **3ac-6** was obtained as a white solid (42.5 mg, 46%). $R_f = 0.70$ (n-hexane/EtOAc 3:1). m.p. 209.0–211.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.30 (s, 1H), 8.59 (d, $J = 7.6$ Hz, 1H), 8.41 (d, $J = 4.8$ Hz, 1H), 8.29 (d, $J = 7.6$ Hz, 1H), 7.82–7.71 (m, 4H), 7.63 (d, $J = 8.0$ Hz, 2H), 7.55 (t, $J = 8.0$ Hz, 1H), 7.52–7.46 (m, 3H), 7.27 (d, $J = 8.0$ Hz, 1H), 7.25–7.21 (m, 1H), 6.84 (d, $J = 16.0$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 165.0, 162.2, 150.2, 147.6, 146.0, 144.8, 137.6, 137.4, 137.3, 136.5, 132.2 (q, $J_{\text{C-F}} = 32.5$ Hz), 132.1, 128.3, 127.3, 126.5, 126.1, 125.8 (q, $J_{\text{C-F}} = 3.8$ Hz), 125.5, 125.4, 123.7 (q, $J_{\text{C-F}} = 270.5$ Hz), 122.8, 120.6, 120.2, 119.8. $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -62.9. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{26}\text{H}_{18}\text{F}_3\text{N}_2\text{O}_3$: 463.1270; found: 463.1264. FT-IR (neat, cm^{-1}) ν 3350, 2922, 1737, 1683, 1532, 1500, 1324, 1114, 750.



8-(picolinamido)naphthalen-1-yl

3-(2-bromophenyl)acrylate


(**3ac-7**). Following the general procedure, **3ac-7** was obtained as a yellow solid (62.3 mg, 66%). $R_f = 0.48$ (n-hexane/EtOAc 3:1). m.p. 151.0–153.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.35 (s, 1H), 8.61 (d, $J = 7.6$ Hz, 1H), 8.38 (d, $J = 4.4$ Hz, 1H), 8.30 (d, $J = 7.6$ Hz, 1H), 8.15 (d, $J = 15.6$ Hz, 1H), 7.82–7.71 (m, 3H), 7.64–7.59 (m, 1H), 7.55 (t, $J = 8.0$ Hz, 1H), 7.49 (t, $J = 8.0$ Hz, 1H), 7.39–7.34 (m, 1H), 7.31–7.25 (m, 3H), 7.21–7.15 (m, 1H), 6.73 (d, $J = 16.0$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 164.9, 162.3, 150.2, 147.6, 146.1, 145.1, 137.5, 136.4, 134.1, 133.6, 132.2, 131.6, 127.7, 127.6, 127.2, 126.4, 126.0, 125.6, 125.37, 125.36, 122.8, 120.4, 120.3, 120.2, 119.8. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{18}\text{BrN}_2\text{O}_3$: 473.0501; found: 473.0495. FT-IR (neat, cm^{-1}) ν 3341, 2922, 1735, 1680, 1527, 1494, 1114, 750.



8-(picolinamido)naphthalen-1-yl


(**3ad-1**). Following the general procedure, **3ad-1** was obtained as a white solid (74.2 mg, 77%). $R_f = 0.84$ (n-hexane/EtOAc 3:1). m.p. 154.0–156.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.6 (s, 1H), 8.79 (d, $J = 7.6$ Hz, 1H), 8.77 (d, $J = 4.4$ Hz, 1H), 8.38 (d, $J = 7.6$ Hz, 1H), 7.95 (dt, $J = 7.6, 1.2$ Hz, 1H), 7.75 (d, $J = 7.6$ Hz, 1H), 7.67 (d, $J = 8.0$ Hz, 1H), 7.57–7.49 (m, 2H), 7.46 (t, $J = 8.0$ Hz, 1H), 7.20 (dd, $J = 7.6, 0.8$ Hz, 1H), 5.03 (s, 1H), 3.16–3.06 (m, 1H), 2.45 (s, 1H), 1.97–1.72 (m, 4H), 1.68 (s, 3H), 1.58–1.44 (m, 3H), 1.38–1.29 (m, 1H), 1.24–1.19 (m, 1H), 1.09 (d, $J = 7.2$ Hz, 3H), 0.97–0.87 (m, 2H), 0.84 (d, $J = 6.4$ Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 176.3, 162.1, 150.6, 147.8, 145.8, 137.8, 136.4, 136.0, 132.6, 127.0, 126.5, 126.4, 125.2, 124.8, 123.0, 120.5, 119.5, 119.2, 119.0, 44.1, 41.8, 41.5, 36.5, 35.1, 27.6, 27.4, 26.5, 25.6, 23.9, 19.6, 15.0. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$

calcd for C₃₁H₃₅N₂O₃: 483.2648; found: 483.2642. FT-IR (neat, cm⁻¹) ν 3342, 2918, 1764, 1686, 1532, 1498, 1105, 1040, 753.




8-(picolinamido)naphthalen-1-yl
(*S*)-2-(6-methoxynaphthalen-2-yl)propanoate
(**3ad-2**). Following the general procedure, **3ad-2** was obtained as a white solid (87.6 mg, 92%). R_f = 0.50 (n-hexane/EtOAc 3:1). m.p. 146.0–148.0 °C.

¹H NMR (400 MHz, CDCl₃) δ 11.58 (s, 1H), 8.84–8.71 (m, 2H), 8.41 (d, J = 7.6 Hz, 1H), 7.97 (dt, J = 7.6, 1.6 Hz, 1H), 7.79–7.64 (m, 5H), 7.59–7.51 (m, 3H), 7.31 (t, J = 8.0 Hz, 1H), 7.21–7.12 (m, 2H), 6.77 (dd, J = 7.6, 1.2 Hz, 1H), 4.67 (q, J = 7.2 Hz, 1H), 3.93 (s, 3H), 1.53 (d, J = 7.2 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 173.4, 162.2, 157.8, 150.5, 147.6, 146.3, 137.9, 136.3, 134.6, 133.9, 132.4, 129.3, 129.0, 127.5, 127.1, 126.7, 126.4, 126.2, 126.1, 125.2, 125.0, 123.1, 119.7, 119.5, 119.3, 119.2, 105.6, 55.3, 45.1, 18.0. HRMS (ESI): m/z [M+H]⁺ calcd for C₃₀H₂₅N₂O₄: 477.1814; found: 477.1809. FT-IR (neat, cm⁻¹) ν 3355, 2933, 1763, 1685, 1531, 1497, 1109, 753.



8-(picolinamido)naphthalen-1-yl
2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate (**3ad-3**). Following the general procedure, **3ad-3** was obtained as a yellow solid (83.5 mg, 74%). R_f = 0.48


(n-hexane/EtOAc 3:1). m.p. 163.0–165.0 °C. ¹H NMR (400 MHz, CDCl₃) δ 10.82 (s, 1H), 8.67 (d, J = 4.4 Hz, 1H), 8.51 (d, J = 7.6 Hz, 1H), 8.27 (d, J = 7.6 Hz, 1H), 7.91 (t, J = 7.6 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.72–7.65 (m, 5H), 7.55–7.43 (m, 5H), 7.14 (d, J = 7.2 Hz, 1H), 6.86 (d, J = 8.8 Hz, 2H), 1.68 (s, 6H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 194.2, 172.8, 162.6, 159.0, 150.1, 147.9, 146.0, 138.5, 137.7, 136.5, 136.2, 132.0, 131.9, 131.2, 131.1, 128.6, 127.6, 126.6, 126.5, 125.5, 125.2, 122.9, 120.4, 120.2, 120.0, 118.5, 79.9, 25.2. HRMS (ESI): m/z [M-H]⁻ calcd for C₃₃H₂₄ClN₂O₅: 563.1374; found: 563.1379. FT-IR (neat, cm⁻¹) ν 3341, 2923, 1737, 1652, 1594, 1543, 1504, 1251, 1145, 758.



8-(Picolinamido)naphthalen-1-yl (*2E*, *4E*)-hexa-2,4-dienoate (**3ad-4**). Following the general procedure, **3ad-4** was obtained as a yellow solid (27.2 mg, 38%). R_f = 0.50 (n-hexane/EtOAc 3:1). m.p. 145.0–147.0 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.56 (s, 1H), 8.74 (d, J


= 7.6 Hz, 1H), 8.56 (d, J = 4.0 Hz, 1H), 8.31 (d, J = 7.6 Hz, 1H), 7.87 (t, J = 7.6 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.53 (t, J = 8.0 Hz, 1H), 7.48–7.36 (m, 3H), 7.21 (d, J = 7.6 Hz, 1H), 6.26–6.10 (m, 3H), 1.87 (d, J = 4.8 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 165.9, 162.3, 150.3, 147.6, 147.3, 146.3,

141.3, 137.5, 136.4, 132.6, 129.4, 126.9, 126.4, 126.2, 125.3, 125.0, 122.7, 120.1, 119.50, 119.46, 118.4, 18.8. HRMS (ESI): m/z $[M+H]^+$ calcd for $C_{22}H_{19}N_2O_3$: 359.1396; found: 359.1390. FT-IR (neat, cm^{-1}) ν 3332, 2923, 1724, 1677, 1526, 1494, 1111, 1000, 740.



8-(Picolinamido)naphthalen-1-yl


2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylate (**3ad-5**). Following the general procedure, **3ad-5** was obtained as a yellow solid (30.7 mg, 28%). $R_f = 0.23$ (n-hexane/EtOAc 3:1). m.p. 190.0–192.0 °C. 1H NMR (400 MHz, DMSO- d_6) δ 10.7 (s, 1H), 8.19 (d, $J = 2.4$ Hz, 1H), 8.10 (dd, $J = 8.8, 2.4$ Hz, 1H), 8.08–8.04 (m, 1H), 8.02–7.94 (m, 3H), 7.87 (d, $J = 7.2$ Hz, 1H), 7.78 (dt, $J = 7.8, 1.6$ Hz, 1H), 7.65–7.56 (m, 2H), 7.14 (dd, $J = 7.2, 1.2$ Hz, 1H), 7.37 (d, $J = 8.8, 1H$), 7.26–7.21 (m, 1H), 4.02 (d, $J = 6.8$ Hz, 2H), 2.55 (s, 3H), 2.16–2.06 (m, 1H), 1.04 (d, $J = 6.8$ Hz, 6H). $^{13}C\{^1H\}$ NMR (100 MHz, DMSO- d_6) δ 168.1, 163.0, 162.7, 162.1, 160.8, 149.6, 147.9, 145.9, 138.0, 136.4, 133.7, 132.1, 132.0, 128.0, 127.1, 126.8, 126.7, 126.3, 125.4, 125.0, 122.6, 122.3, 121.3, 121.2, 115.8, 114.4, 102.1, 75.6, 28.1, 19.2, 17.8. HRMS (ESI): m/z $[M+H]^+$ calcd for $C_{32}H_{27}N_4O_4S$: 563.1753; found: 563.1748. FT-IR (neat, cm^{-1}) ν 3356, 2928, 1731, 1686, 1531, 1500, 1430, 1289, 1246, 1030, 753.



8-(picolinamido)naphthalen-1-yl


(1R,3R)-3-((Z)-2-chloro-3,3,3-trifluoroprop-1-en-1-yl)-2,2-dimethylcyclopropane-1-carboxylate (**3ad-6**).

Following the general procedure, **3ad-6** was obtained as a white solid (76.1 mg, 78%). $R_f = 0.64$ (n-hexane/EtOAc 3:1). m.p. 123.0–125.0 °C. 1H NMR (400 MHz, $CDCl_3$) δ 11.46 (s, 1H), 8.69 (d, $J = 7.6$ Hz, 1H), 8.64 (d, $J = 4.4$ Hz, 1H), 8.40 (d, $J = 7.6$ Hz, 1H), 7.96 (t, $J = 7.6$ Hz, 1H), 7.78 (d, $J = 8.4$ Hz, 1H), 7.70 (d, $J = 8.4$ Hz, 1H), 7.57–7.51 (m, 2H), 7.47 (t, $J = 8.4$ Hz, 1H), 7.18 (d, $J = 7.6$ Hz, 1H), 6.76 (d, $J = 9.2$ Hz, 1H), 2.57 (d, $J = 8.0$ Hz, 1H), 1.96 (t, $J = 8.4$ Hz, 1H), 1.22 (s, 3H), 1.04 (s, 3H). $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 168.9, 161.9, 150.3, 147.7, 145.6, 137.9, 136.4, 132.3, 128.9 (q, $J_{C-F} = 4.4$ Hz), 127.3, 126.6, 126.5, 125.2, 125.1, 123.1, 122.4 (q, $J_{C-F} = 37.6$ Hz), 120.6, 120.1 (q, $J_{C-F} = 269.8$ Hz), 119.7, 119.4, 32.6, 31.8, 29.9, 27.9, 14.6. ^{19}F NMR (376 MHz, $CDCl_3$) δ -68.8. HRMS (ESI): m/z $[M+H]^+$ calcd for $C_{25}H_{21}ClF_3N_2O_3$: 489.1193; found: 489.1187. FT-IR (neat, cm^{-1}) ν 3348, 2932, 1751, 1687, 1532, 1499, 1275, 1115, 1059, 753.




8-(3-methylpicolinamido)naphthalen-1-yl acetate (**3ba**). Following the general procedure, **3ba** was obtained as a white solid (31.4 mg, 49%). $R_f = 0.50$ (n-hexane/EtOAc 3:1). m.p. 147.0–149.0 °C. 1H


NMR (400 MHz, CDCl₃) δ 11.49 (s, 1H), 8.65 (d, J = 7.6 Hz, 1H), 8.50 (d, J = 4.0 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.67 (d, J = 8.0 Hz, 2H), 7.52 (t, J = 8.0 Hz, 1H), 7.45 (t, J = 8.0 Hz, 1H), 7.39 (dd, J = 7.6, 4.8 Hz, 1H), 7.17 (dd, J = 7.6, 0.8 Hz, 1H), 2.85 (s, 3H), 2.33 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 169.5, 163.8, 147.4, 145.9, 145.1, 141.4, 136.5, 136.4, 132.6, 127.2, 126.4, 126.1, 125.2, 124.9, 120.3, 119.63, 119.57, 21.5, 21.0. HRMS (ESI): m/z [M+H]⁺ calcd for C₁₉H₁₇N₂O₃: 321.1239; found: 321.1234. FT-IR (neat, cm⁻¹) ν 3346, 2924, 1769, 1682, 1524, 1494, 1430, 1081, 759.



8-(4-methylpicolinamido)naphthalen-1-yl acetate (**3ca**). Following the general procedure, **3ca** was obtained as a white solid (39.7 mg, 62%). R_f = 0.48 (n-hexane/EtOAc 3:1). m.p. 159.0–161.0 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.51 (s, 1H), 8.76 (dd, J = 8.0, 0.8 Hz, 1H), 8.49 (d, J = 4.8 Hz, 1H), 8.19 (s, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.53 (t, J = 8.0 Hz, 1H), 7.45 (t, J = 8.0 Hz, 1H), 7.31 (d, J = 4.8 Hz, 1H), 7.19 (dd, J = 7.6, 1.2 Hz, 1H), 2.48 (s, 3H), 2.45 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 169.6, 162.5, 150.0, 149.3, 147.4, 145.9, 136.4, 132.5, 127.4, 127.2, 126.4, 125.2, 124.9, 123.7, 120.4, 119.4, 119.2, 21.6, 21.2. HRMS (ESI): m/z [M+H]⁺ calcd for C₁₉H₁₇N₂O₃: 321.1239; found: 321.1234. FT-IR (neat, cm⁻¹) ν 3337, 2934, 1763, 1671, 1528, 1496, 1432, 1179, 1024, 759.




8-(5-methylpicolinamido)naphthalen-1-yl acetate (**3da**). Following the general procedure, **3da** was obtained as a white solid (46.7 mg, 73%). R_f = 0.46 (n-hexane/EtOAc 3:1). m.p. 155.0–157.0 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.46 (s, 1H), 8.77 (d, J = 7.6 Hz, 1H), 8.45 (s, 1H), 8.25 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.72 (dd, J = 8.0, 1.2 Hz, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.52 (t, J = 8.0 Hz, 1H), 7.45 (t, J = 8.0 Hz, 1H), 7.19 (d, J = 7.6 Hz, 1H), 2.46 (s, 3H), 2.44 (s, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 169.6, 162.5, 148.1, 147.9, 145.9, 138.1, 136.9, 136.4, 132.6, 127.2, 126.4, 125.2, 124.9, 122.5, 120.3, 119.3, 119.1, 21.7, 18.6. HRMS (ESI): m/z [M+H]⁺ calcd for C₁₉H₁₇N₂O₃: 321.1239; found: 321.1234. FT-IR (neat, cm⁻¹) ν 3331, 2922, 1766, 1673, 1530, 1499, 1185, 757.




8-(6-methylpicolinamido)naphthalen-1-yl acetate (**3ea**). Following the general procedure, **3ea** was obtained as a gray solid (14.7 mg, 23%). R_f = 0.46 (n-hexane/EtOAc 3:1). m.p. 168.0–170.0 °C. ¹H NMR (400 MHz, CDCl₃) δ 11.19 (s, 1H), 8.53 (d, J = 7.6 Hz, 1H), 8.19 (d, J = 7.6 Hz, 1H), 7.83 (t, J = 7.6 Hz, 1H), 7.78 (d, J = 7.6 Hz, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.53 (t, J = 8.0 Hz, 1H), 7.47 (t, J = 8.0 Hz, 1H), 7.38 (d, J = 7.6 Hz, 1H), 7.19 (dd, J = 7.2, 0.8 Hz, 1H), 2.69 (s, 3H),

2.22 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.4, 162.5, 157.0, 149.6, 145.8, 138.0, 136.4, 132.0, 127.3, 126.4, 125.4, 125.3, 120.6, 120.5, 120.2, 120.0, 24.2, 21.2. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{17}\text{N}_2\text{O}_3$: 321.1239; found: 321.1234. FT-IR (neat, cm^{-1}) ν 3362, 2924, 1772, 1687, 1530, 1497, 1179, 746.




8-(4-methoxypicolinamido)naphthalen-1-yl acetate (**3fa**).

Following the general procedure, **3fa** was obtained as a yellow solid (52.4 mg, 78%). R_f = 0.40 (n-hexane/EtOAc 3:1). m.p. 157.0–159.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 11.53 (s, 1H), 8.75 (dd, J = 8.0, 1.2 Hz, 1H), 8.43 (d, J = 5.6 Hz, 1H), 7.90 (d, J = 2.8 Hz, 1H), 7.76 (dd, J = 8.0, 0.8 Hz, 1H), 7.68 (d, J = 8.0, 0.8 Hz, 1H), 7.53 (t, J = 8.0 Hz, 1H), 7.45 (t, J = 8.0 Hz, 1H), 7.19 (dd, J = 7.6, 1.2 Hz, 1H), 7.00 (dd, J = 5.6, 2.8 Hz, 1H), 3.95 (s, 3H), 2.45 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.6, 167.3, 162.2, 152.3, 148.8, 145.9, 136.4, 132.4, 127.2, 126.4, 125.2, 125.0, 120.4, 119.4, 119.2, 113.4, 107.9, 55.6, 21.7. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{17}\text{N}_2\text{O}_4$: 337.1188; found: 337.1183. FT-IR (neat, cm^{-1}) ν 3342, 2927, 1772, 1682, 1529, 1496, 1180, 1030, 758.




8-(4-chloropicolinamido)naphthalen-1-yl acetate (**3ga**).

Following the general procedure, **3ga** was obtained as a yellow solid (48.3 mg, 71%). R_f = 0.72 (n-hexane/EtOAc 3:1). m.p. 184.0–186.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 11.44 (s, 1H), 8.75 (d, J = 7.6 Hz, 1H), 8.53 (d, J = 5.2 Hz, 1H), 8.37 (d, J = 2.0 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.55–7.50 (m, 2H), 7.46 (t, J = 8.0 Hz, 1H), 7.20 (dd, J = 7.6, 0.8 Hz, 1H), 2.44 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.4, 161.1, 151.8, 148.6, 146.5, 145.8, 136.4, 132.2, 127.3, 126.8, 126.5, 125.4, 125.3, 123.6, 120.5, 119.5, 119.1, 21.7. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{14}\text{ClN}_2\text{O}_3$: 341.0693; found: 341.0687. FT-IR (neat, cm^{-1}) ν 3350, 2930, 1763, 1672, 1542, 1501, 1194, 1027, 754.




8-(4-bromopicolinamido)naphthalen-1-yl acetate (**3ha**).


Following the general procedure, **3ha** was obtained as a yellow solid (55.4 mg, 72%). R_f = 0.72 (n-hexane/EtOAc 3:1). m.p. 178.0–180.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 11.42 (s, 1H), 8.74 (d, J = 7.6 Hz, 1H), 8.53 (d, J = 1.6 Hz, 1H), 8.44 (d, J = 4.8 Hz, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.71–7.65 (m, 2H), 7.53 (t, J = 8.0 Hz, 1H), 7.46 (t, J = 8.0 Hz, 1H), 7.19 (d, J = 7.6 Hz, 1H), 2.44 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.4, 160.9, 151.4, 148.3, 145.7, 136.3, 135.0, 132.1, 129.8, 127.2, 126.6, 126.4, 125.32, 125.30, 120.5, 119.5, 119.0, 21.7. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{14}\text{BrN}_2\text{O}_3$: 385.0188; found: 385.0182. FT-IR (neat, cm^{-1}) ν 3346, 2952, 1759, 1668, 1538, 1497, 1189, 1024, 753.




8-(4-(trifluoromethyl)picolinamido)naphthalen-1-yl acetate (**3ia**). Following the general procedure, **3ia** was obtained as a gray solid (53.2 mg, 78%). $R_f = 0.75$ (n-hexane/EtOAc 3:1). m.p. 170.0–172.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.47 (s, 1H), 8.84–8.80 (m, 1H), 8.78 (dd, $J = 8.0, 1.2$ Hz, 1H), 6.62 (s, 1H), 7.78–7.73 (m, 2H), 7.70 (d, $J = 8.0$ Hz, 1H), 7.54 (t, $J = 8.0$ Hz, 1H), 7.47 (t, $J = 8.0$ Hz, 1H), 7.21 (d, $J = 7.6$ Hz, 1H), 2.45 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.3, 160.8, 151.9, 148.7, 145.7, 140.4 (q, $J = 34.8$ Hz), 136.4, 132.0, 127.3, 126.4, 125.45, 125.36, 122.4 (q, $J = 271.9$ Hz), 122.2 (q, $J = 3.4$ Hz), 125.5, 119.5, 119.1 (q, $J = 3.5$ Hz), 119.0, 21.7. $^{19}\text{F NMR}$ (376 MHz, CDCl_3) δ -64.8. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{14}\text{F}_3\text{N}_2\text{O}_3$: 375.0957; found: 375.0951. FT-IR (neat, cm^{-1}) ν 3348, 2924, 1774, 1685, 1534, 1501, 1408, 1330, 1174, 1139, 757.



8-(isoquinoline-1-carboxamido)naphthalen-1-yl acetate (**3ja**). Following the general procedure, **3ja** was obtained as a yellow solid (62.7 mg, 88%). $R_f = 0.70$ (n-hexane/EtOAc 3:1). m.p. 159.0–161.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.64 (s, 1H), 9.80–9.70 (m, 1H), 8.73 (dd, $J = 8.0, 1.2$ Hz, 1H), 8.58 (d, $J = 5.6$ Hz, 1H), 7.94–7.87 (m, 2H), 7.80–7.69 (m, 4H), 7.57 (t, $J = 8.0$ Hz, 1H), 7.47 (t, $J = 8.0$ Hz, 1H), 7.20 (dd, $J = 7.8, 1.2$ Hz, 1H), 2.30 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.5, 163.9, 148.2, 145.9, 139.6, 137.6, 136.4, 132.5, 130.8, 129.1, 127.9, 127.33, 127.25, 127.0, 126.4, 125.3, 125.15, 125.08, 120.4, 119.8, 119.6, 21.5. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{17}\text{N}_2\text{O}_3$: 357.1239; found: 357.1234. FT-IR (neat, cm^{-1}) ν 3338, 2928, 1768, 1676, 1524, 1491, 1181, 754.




8-(quinoline-2-carboxamido)naphthalen-1-yl acetate (**3ka**). Following the general procedure, **3ka** was obtained as a white solid (14.2 mg, 20%). $R_f = 0.68$ (n-hexane/EtOAc 3:1). m.p. 184.0–186.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.51 (s, 1H), 8.66 (d, $J = 7.6$ Hz, 1H), 8.49 (d, $J = 8.4$ Hz, 1H), 8.42 (d, $J = 8.4$ Hz, 1H), 8.26 (d, $J = 8.4$ Hz, 1H), 7.96 (d, $J = 8.4$ Hz, 1H), 7.87–7.82 (m, 1H), 7.80 (d, $J = 8.0$ Hz, 1H), 7.73–7.66 (m, 2H), 7.56 (t, $J = 8.0$ Hz, 1H), 7.49 (t, $J = 8.0$ Hz, 1H), 7.22 (dd, $J = 7.2, 0.8$ Hz, 1H), 2.21 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.5, 162.3, 150.2, 146.1, 145.9, 138.0, 136.4, 132.2, 130.6, 129.5, 129.4, 128.2, 128.1, 127.3, 126.5, 125.4, 125.3, 120.6, 120.2, 119.8, 119.2, 21.5. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{17}\text{N}_2\text{O}_3$: 357.1239; found: 357.1234. FT-IR (neat, cm^{-1}) ν 3325, 2924, 1768, 1682, 1529, 1493, 1184, 758.




4-bromo-8-(picolinamido)naphthalen-1-yl acetate (**3ma**).

Following the general procedure, **3ma** was obtained as a white solid (62.4 mg, 81%). $R_f = 0.50$ (n-hexane/EtOAc 3:1). m.p. 161.0–163.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.51 (s, 1H), 8.82 (dd, $J = 8.0, 1.2$ Hz, 1H), 8.67–8.62 (m, 1H), 8.37 (d, $J = 7.6$ Hz, 1H), 8.14 (dd, $J = 8.4, 0.8$ Hz, 1H), 7.95 (dt, $J = 7.6, 1.6$ Hz, 1H), 7.79 (d, $J = 8.4$ Hz, 1H), 7.65 (t, $J = 8.0$ Hz, 1H), 7.55–7.50 (m, 1H), 7.06 (d, $J = 8.0$ Hz, 1H), 2.43 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.2, 162.3, 150.1, 147.7, 145.6, 137.9, 134.1, 132.9, 129.5, 127.9, 126.7, 124.5, 123.0, 121.0, 120.6, 120.5, 120.4, 21.5. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{14}\text{BrN}_2\text{O}_3$: 385.0188; found: 385.0182. FT-IR (neat, cm^{-1}) ν 3337, 2923, 1770, 1685, 1533, 1493, 1174, 741.




5-chloro-8-(picolinamido)naphthalen-1-yl acetate (**3na**).

Following the general procedure, **3na** was obtained as a white solid (37.4 mg, 55%). $R_f = 0.50$ (n-hexane/EtOAc 3:1). m.p. 169.0–171.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.54 (s, 1H), 8.73 (d, $J = 8.4$ Hz, 1H), 8.64 (d, $J = 4.8$ Hz, 1H), 8.35 (d, $J = 8.0$ Hz, 1H), 8.26 (d, $J = 8.4$ Hz, 1H), 7.94 (dt, $J = 7.6, 1.2$ Hz, 1H), 7.63 (d, $J = 8.4$ Hz, 1H), 7.58 (t, $J = 8.4$ Hz, 1H), 7.54–7.49 (m, 1H), 7.26 (d, $J = 7.6$ Hz, 1H), 2.45 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.3, 162.2, 150.0, 147.6, 146.1, 137.9, 133.1, 131.9, 127.8, 126.9, 126.7, 126.3, 123.6, 123.0, 121.4, 120.3, 119.0, 21.6. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{14}\text{ClN}_2\text{O}_3$: 341.0693; found: 341.0687. FT-IR (neat, cm^{-1}) ν 3348, 2922, 1755, 1686, 1531, 1499, 1198, 750.



5-bromo-8-(picolinamido)naphthalen-1-yl acetate (**3oa**).


Following the general procedure, **3oa** was obtained as a white solid (67.0 mg, 87%). $R_f = 0.50$ (n-hexane/EtOAc 3:1). m.p. 177.0–179.0 °C. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.58 (s, 1H), 8.69 (d, $J = 8.4$ Hz, 1H), 8.66 (d, $J = 4.4$ Hz, 1H), 8.36 (d, $J = 8.0$ Hz, 1H), 8.26 (dd, $J = 8.4, 0.8$ Hz, 1H), 7.96 (dt, $J = 7.6, 1.6$ Hz, 1H), 7.84 (d, $J = 8.4$ Hz, 1H), 7.58 (t, $J = 7.6$ Hz, 1H), 7.55–7.51 (m, 1H), 7.27 (dd, $J = 7.6, 0.8$ Hz, 1H), 2.46 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.3, 162.2, 150.0, 147.7, 146.0, 137.9, 134.1, 132.6, 130.7, 126.8, 126.6, 126.5, 123.0, 121.4, 120.4, 119.5, 118.4, 21.6. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{14}\text{BrN}_2\text{O}_3$: 385.0188; found: 385.0182. FT-IR (neat, cm^{-1}) ν 3339, 2927, 1771, 1683, 1522, 1493, 1176, 750.



5-methyl-8-(picolinamido)naphthalen-1-yl acetate (**3pa**).

Following the general procedure, **3pa** was obtained as a white


solid (55.0 mg, 86%). $R_f = 0.48$ (n-hexane/EtOAc 3:1). m.p. 154.0–156.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 11.40 (s, 1H), 8.64 (d, $J = 4.4$ Hz, 1H), 8.60 (d, $J = 7.6$ Hz, 1H), 8.36 (d, $J = 8.0$ Hz, 1H), 8.00–7.89 (m, 2H), 7.53–7.47 (m, 2H), 7.39 (d, $J = 8.0$ Hz, 1H), 7.20 (d, $J = 8.0$ Hz, 1H), 2.67 (s, 3H), 2.41 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.6, 162.1, 150.3, 147.6, 146.3, 137.7, 135.2, 131.1, 130.7, 127.3, 126.5, 125.0, 123.2, 122.8, 120.2, 119.6, 119.5, 21.6, 20.0. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{17}\text{N}_2\text{O}_3$: 321.1239; found: 321.1234. FT-IR (neat, cm^{-1}) ν 3335, 2925, 1764, 1676, 1528, 1505, 1181, 747.



5-methoxy-8-(picolinamido)naphthalen-1-yl acetate (**3qa**).

Following the general procedure, **3qa** was obtained as a yellow solid (55.1 mg, 82%). $R_f = 0.37$ (n-hexane/EtOAc 3:1). m.p. 138.0–140.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 11.14 (s, 1H), 8.66–8.59 (m, 1H), 8.51 (d, $J = 8.8$ Hz, 1H), 8.35 (d, $J = 7.6$ Hz, 1H), 8.26 (dd, $J = 8.8, 1.6$ Hz, 1H), 7.91 (dd, $J = 7.6, 1.6$ Hz,


1H), 7.51–7.42 (m, 2H), 7.22 (d, $J = 7.6, 1.2$ Hz, 1H), 6.88 (d, $J = 8.4$ Hz, 1H), 4.00 (s, 3H), 2.36 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.6, 162.1, 152.6, 150.4, 147.6, 145.7, 137.7, 128.0, 126.4, 124.9, 124.7, 122.7, 121.2, 120.92, 120.87, 120.7, 104.2, 55.7, 21.5. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{17}\text{N}_2\text{O}_4$: 337.1188; found: 337.1183. FT-IR (neat, cm^{-1}) ν 3350, 2933, 1763, 1670, 1538, 1506, 1185, 1038, 749.



3-(picolinamido)pyren-4-yl acetate (**3ra**). Following the general procedure, **3ra** was obtained as a yellow solid (62.3 mg, 82%). $R_f = 0.26$ (n-hexane/EtOAc 3:1). m.p. 214.0–216.0

°C. ^1H NMR (400 MHz, CDCl_3) δ 11.75 (s, 1H), 9.25 (d, $J = 8.8$ Hz, 1H), 8.70 (d, $J = 4.4$ Hz, 1H), 8.42 (d, $J = 7.6$ Hz, 1H), 8.24 (d, $J = 8.8$ Hz, 1H), 8.13 (d, $J = 7.6$ Hz, 1H), 8.07 (d, $J =$

7.2 Hz, 1H), 8.04–7.92 (m, 4H), 7.76 (s, 1H), 7.56–7.09 (m, 1H), 2.49 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.6, 162.3, 150.3, 147.8, 145.0, 137.9, 131.6, 131.3, 130.4, 128.5, 127.6, 127.1, 126.7, 126.6, 126.5, 125.3, 124.4, 123.6, 123.1, 120.8, 120.5, 116.1, 21.8. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{17}\text{N}_2\text{O}_3$: 381.1239; found: 381.1234. FT-IR (neat, cm^{-1}) ν 3340, 2927, 1770, 1682, 1517, 1492, 1180, 746.




10-(picolinamido)phenanthren-1-yl acetate (**3sa**). Following the general procedure, **3sa** was obtained as a white solid (57.0 mg, 80%). $R_f = 0.27$ (n-hexane/EtOAc 3:1). m.p. 191.0–193.0 °C. ^1H


NMR (400 MHz, CDCl_3) δ 11.58 (s, 1H), 9.11 (s, 1H), 8.71–8.65 (m, 2H), 8.62–8.56 (m, 1H), 8.40 (d, $J = 8.0$ Hz, 1H), 7.95 (dt, $J = 8.0, 1.2$ Hz, 1H), 7.92–7.87 (m, 1H), 7.66 (t, $J = 8.0$ Hz, 1H),

7.63–7.57 (m, 2H), 7.55–7.50 (m, 1H), 7.32 (d, $J = 7.6$ Hz, 1H), 2.46 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.6, 162.5, 150.3, 147.7, 146.5, 137.9, 133.6, 131.9,


130.0, 128.6, 127.7, 127.5, 126.6, 126.4, 126.2, 122.9, 122.7, 121.7, 121.6, 119.3, 119.2, 21.6. HRMS (ESI): m/z $[M+H]^+$ calcd for $C_{22}H_{17}N_2O_3$: 357.1239; found: 357.1234. FT-IR (neat, cm^{-1}) ν 3347, 2940, 1771, 1683, 1523, 1169, 755.




6-(picolinamido)-1,2-dihydroacenaphthylen-5-yl acetate (**3ta**). Following the general procedure, **3ta** was obtained as a white solid (35.5 mg, 53%). R_f = 0.30 (n-hexane/EtOAc 3:1). m.p. 161.0–163.0 °C. 1H NMR (400 MHz, $CDCl_3$) δ 11.28 (s, 1H), 8.74 (d, J = 8.0 Hz, 1H), 8.64 (d, J = 4.4 Hz, 1H), 8.37 (d, J = 8.0 Hz, 1H), 7.94 (dt, J = 7.6, 1.6 Hz, 1H), 7.53–7.49 (m, 1H), 7.33 (d, J = 8.0 Hz, 1H), 7.25 (d, J = 7.26 Hz, 1H), 7.16 (d, J = 7.6 Hz, 1H), 3.39 (s, 4H), 2.52 (s, 3H). $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 169.9, 162.1, 150.4, 147.6, 144.4, 142.6, 142.1, 141.5, 137.8, 129.1, 126.4, 122.8, 121.4, 120.4, 120.1, 119.1, 117.3, 30.3, 30.1, 21.6. HRMS (ESI): m/z $[M+H]^+$ calcd for $C_{20}H_{17}N_2O_3$: 333.1239; found: 333.1234. FT-IR (neat, cm^{-1}) ν 3335, 2929, 1767, 1671, 1528, 1498, 1179, 753.



4-(picolinamido)fluoranthren-3-yl acetate (**3ua**). Following the general procedure, **3ua** was obtained as a yellow solid (31.9 mg, 42%). R_f = 0.27 (n-hexane/EtOAc 3:1). m.p. 225.0–227.0 °C. 1H NMR (400 MHz, $CDCl_3$) δ 11.62 (s, 1H), 9.05 (d, J = 8.0 Hz, 1H), 8.64 (d, J = 4.8 Hz, 1H), 8.40 (d, J = 8.0 Hz, 1H), 8.00–7.83 (m, 5H), 7.56–7.51 (m, 1H), 7.40–7.31 (m, 3H), 2.64 (s, 3H). $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 169.3, 162.3, 150.2, 147.6, 146.1, 139.1, 138.4, 137.9, 135.1, 134.1, 133.8, 132.6, 127.5, 127.1, 126.7, 123.0, 121.7, 121.3, 121.2, 121.1, 120.0, 119.0, 115.8, 21.8. HRMS (ESI): m/z $[M+H]^+$ calcd for $C_{24}H_{17}N_2O_3$: 381.1239; found: 381.1234. FT-IR (neat, cm^{-1}) ν 3333, 2924, 1762, 1676, 1529, 1443, 1187, 1039, 750.




8-(pyrazine-2-carboxamido)naphthalen-1-yl acetate (**3va**). Following the general procedure, **3va** was obtained as a white solid (17.8 mg, 29%). R_f = 0.22 (n-hexane/EtOAc 3:1). m.p. 171.0–173.0 °C. 1H NMR (400 MHz, $CDCl_3$) δ 11.32 (s, 1H), 9.60 (s, 1H), 8.85 (d, J = 2.0 Hz, 1H), 8.78 (d, J = 8.0 Hz, 1H), 8.61 (s, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.71 (d, J = 8.4 Hz, 1H), 7.54 (t, J = 8.0 Hz, 1H), 7.47 (t, J = 8.0 Hz, 1H), 7.21 (d, J = 7.2 Hz, 1H), 2.46 (s, 3H). $^{13}C\{^1H\}$ NMR (100 MHz, $CDCl_3$) δ 169.2, 160.8, 147.6, 145.7, 145.3, 144.9, 141.9, 136.4, 132.0, 127.3, 126.4, 125.5, 125.4, 120.6, 119.5, 118.9, 21.7. HRMS (ESI): m/z $[M+H]^+$ calcd for $C_{17}H_{14}N_3O_3$: 308.1035; found: 308.1030. FT-IR (neat, cm^{-1}) ν 3337, 2925, 1764, 1680, 1534, 1498, 1174, 1020, 754.




8-(pyrimidine-4-carboxamido)naphthalen-1-yl acetate (**3wa**). Following the general procedure, **3wa** was obtained as a yellow solid (35.6 mg, 58%). R_f = 0.22 (n-hexane/EtOAc 3:1). m.p.

189.0–191.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 11.50 (s, 1H), 9.34 (s, 1H), 9.06 (d, $J = 4.8$ Hz, 1H), 8.77 (d, $J = 8.0$ Hz, 1H), 8.29 (dd, $J = 4.8, 1.6$ Hz, 1H), 7.77 (d, $J = 8.0$ Hz, 1H), 7.71 (d, $J = 8.0$ Hz, 1H), 7.53 (t, $J = 7.6$ Hz, 1H), 7.47 (t, $J = 8.0$ Hz, 1H), 7.22 (dd, $J = 7.8, 1.6$ Hz, 1H), 2.50 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.3, 160.4, 159.7, 157.4, 157.8, 145.7, 136.3, 131.8, 124.3, 126.4, 125.7, 125.5, 120.7, 119.5, 119.1, 118.9, 21.8. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{17}\text{H}_{14}\text{N}_3\text{O}_3$: 308.1035; found: 308.1030. FT-IR (neat, cm^{-1}) ν 3328, 2922, 1761, 1676, 1529, 1493, 1180, 756.




4-(picolinamido)naphthalene-1,5-diyl diacetate (**4**).

Following the general procedure, **4** was obtained as a gray solid (29.8 mg, 41%). $R_f = 0.23$ (n-hexane/EtOAc 3:1). m.p. 163.0–165.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 11.51 (s, 1H), 8.78 (d, $J = 8.4$ Hz, 1H), 8.65 (d, $J = 4.4$ Hz, 1H), 8.37 (d, $J = 7.6$ Hz, 1H), 7.95 (t, $J = 7.6$ Hz, 1H), 7.83 (d, $J = 8.4$ Hz, 1H), 7.56–7.48 (m, 2H), 7.33 (d, $J = 8.4$ Hz, 1H), 7.25 (d, $J = 7.2$ Hz, 1H), 2.47 (s, 3H), 2.46 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.4, 169.3, 162.2, 150.2, 147.7, 146.2, 143.0, 137.9, 130.7, 129.4, 126.7, 125.9, 123.0, 121.1, 120.2, 120.0, 119.0, 118.9, 21.6, 21.0. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{17}\text{N}_2\text{O}_5$: 365.1137; found: 365.1132. FT-IR (neat, cm^{-1}) ν 3345, 2926, 1761, 1678, 1530, 1502, 1177, 749.



8-(picolinamido)-5-(trifluoromethyl)naphthalen-1-yl acetate (**5**).


Following the general procedure, **5** was obtained as a gray solid (33.6 mg, 45%). $R_f = 0.25$ (n-hexane/EtOAc 3:1). m.p. 144.0–146.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 10.05 (s, 1H), 8.71 (d, $J = 4.4$ Hz, 1H), 8.35 (d, $J = 7.6$ Hz, 1H), 8.01–7.92 (m, 2H), 7.86 (d, $J = 8.0$ Hz, 1H), 7.78 (d, $J = 8.8$ Hz, 1H), 7.62–7.53 (m, 2H), 7.22 (d, $J = 7.6$ Hz, 1H), 1.79 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 170.1, 164.2, 149.0, 148.4, 146.7, 137.7, 137.6, 130.7 (q, $J = 2.1$ Hz), 129.0, 128.0, 127.4, 127.0, 126.3 (q, $J = 28.9$ Hz), 124.9, 123.7 (q, $J = 272.3$ Hz), 122.9, 122.2, 122.1 (q, $J = 5.0$ Hz), 20.6. ^{19}F NMR (376 MHz, CDCl_3) δ -60.6. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{14}\text{F}_3\text{N}_2\text{O}_3$: 375.0957; found: 375.0951. FT-IR (neat, cm^{-1}) ν 3342, 2936, 1765, 1695, 1495, 1181, 1130, 752.



8-(picolinamido)-5-tosyl naphthalen-1-yl acetate (**6**).


Following the general procedure, **6** was obtained as a gray solid (50.2 mg, 51%). $R_f = 0.13$ (n-hexane/EtOAc 3:1). m.p. 215.0–217.0 °C. ^1H NMR (400 MHz, CDCl_3)

δ 11.95 (s, 1H), 9.06 (d, $J = 8.8$ Hz, 1H), 8.68–8.54 (m, 3H), 8.35 (d, $J = 7.6$ Hz, 1H), 7.95 (t, $J = 7.6$ Hz, 1H), 7.82 (d, $J = 8.0$ Hz, 2H), 7.58–7.49 (m, 2H), 7.27–7.18 (m, 3H), 2.49 (s, 3H), 2.35 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 169.1, 162.7, 149.5, 147.7, 146.4, 144.0, 138.8, 138.7, 138.0, 131.5, 131.4, 131.3, 129.7, 127.5, 127.4, 127.1, 123.25, 123.19, 121.5, 119.2, 116.0, 21.6, 21.5. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{21}\text{N}_2\text{O}_5\text{S}$: 461.1171; found: 461.1166. FT-IR (neat, cm^{-1}) ν 3335, 2925, 1778, 1693, 1521, 1174, 1146, 750.




7

N-(8-hydroxynaphthalen-1-yl)picolinamide (**7**). Following the general procedure, **7** was obtained as a gray solid (42.2 mg, 80%). $R_f = 0.20$ (n-hexane/EtOAc 3:1). m.p. 226.0–228.0 °C. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 13.26 (s, 1H), 11.44 (s, 1H), 8.86 (d, $J = 7.6$ Hz, 1H), 8.74 (d, $J = 4.8$ Hz, 1H), 8.23 (d, $J = 7.6$ Hz, 1H), 8.10 (t, $J = 7.6$ Hz, 1H), 7.68 (dd, $J = 7.6, 4.8$ Hz, 1H), 7.57 (d, $J = 8.4$ Hz, 1H), 7.46 (t, $J = 8.0$ Hz, 1H), 7.37 (d, $J = 8.0$ Hz, 1H), 7.32 (t, $J = 8.0$ Hz, 1H), 6.95 (d, $J = 7.6$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, $\text{DMSO}-d_6$) δ 126.7, 154.0, 150.8, 149.1, 138.7, 136.7, 135.7, 127.4, 127.0, 126.6, 124.0, 122.8, 120.3, 115.8, 115.3, 110.6. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{13}\text{N}_2\text{O}_2$: 265.0977; found: 265.0972. FT-IR (neat, cm^{-1}) ν 2922, 2852, 1655, 1545, 817, 751.




8

N-(8-hydroxynaphthalen-1-yl)acetamide (**8**). Following the general procedure, **8** was obtained as a white solid (44.8 mg, 85%). $R_f = 0.10$ (n-hexane/EtOAc 3:1). m.p. 156.0–158.0 °C. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 11.25 (s, 1H), 11.08 (s, 1H), 8.40 (d, $J = 7.6$ Hz, 1H), 7.49 (dd, $J = 8.0, 0.8$ Hz, 1H), 7.38–7.32 (m, 2H), 7.28 (t, $J = 7.8$ Hz, 1H), 6.89 (dd, $J = 7.8, 1.2$ Hz, 1H), 2.15 (s, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, $\text{DMSO}-d_6$) δ 168.1, 153.8, 136.6, 136.1, 126.8, 126.5, 123.3, 120.4, 115.6, 115.1, 110.6, 25.8. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{12}\text{H}_{12}\text{NO}_2$: 202.0868; found: 202.0863. FT-IR (neat, cm^{-1}) ν 2926, 2854, 1659, 1554, 1433, 1300, 818, 759.




3ha-14

8-(4-bromopicolinamido)naphthalen-1-yl 3-(2-bromophenyl)propanoate (**3ha-14**). Following the general procedure, **3ha-14** was obtained as a white solid (33.7 mg, 42%). $R_f = 0.70$ (n-hexane/EtOAc 3:1). m.p. 134.0–136.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 11.36 (s, 1H), 8.73 (d, $J = 7.6$ Hz, 1H), 8.48 (d, $J = 1.6$ Hz, 1H), 8.24 (d, $J = 5.2$ Hz, 1H), 7.76 (d, $J = 8.4$ Hz, 1H), 7.69 (d, $J = 8.0$ Hz, 1H), 7.58–7.49 (m, 3H), 7.45 (t, $J = 7.6$ Hz, 1H), 7.25–7.08 (m, 4H), 3.12 (s, 4H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 171.3, 160.8, 151.3, 148.4, 145.7, 139.3, 136.4, 134.9, 132.9, 132.2, 123.5, 129.7, 128.3, 127.7, 127.3, 126.6, 126.5, 125.31, 125.27, 124.2, 120.5, 119.5, 119.0, 34.4, 31.0. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{19}\text{Br}_2\text{N}_2\text{O}_3$: 552.9762; found: 552.9757. FT-IR (neat, cm^{-1}) ν 3347, 2926, 1766, 1685, 1529, 1499, 1101, 753.







8-(4-bromopicolinamido)naphthalen-1-yl-3-(2-bromophenyl)acrylate (**3hc-7**). Following the general procedure, **3hc-7** was obtained as a yellow solid (79.5 mg, 72%). $R_f = 0.50$ (n-hexane/EtOAc 3:1). m.p. 157.0–159.0 °C. ^1H NMR (400 MHz, CDCl_3) δ 11.16 (s, 1H), 8.53 (d, $J = 7.6$ Hz, 1H), 8.45 (d, $J = 1.2$ Hz, 1H), 8.18–8.07 (m, 2H), 7.80 (d, $J = 8.0$ Hz, 1H), 7.74 (d, $J = 8.4$ Hz, 1H), 7.64 (d, $J = 7.6$ Hz, 1H), 7.55 (t, $J = 8.0$ Hz, 1H), 7.50 (t, $J = 8.0$ Hz, 1H), 7.41–7.38 (m, 1H), 7.35–7.27 (m, 4H), 6.66 (d, $J = 16.0$ Hz, 1H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 164.8, 161.0, 151.3, 148.2, 146.0, 145.1, 136.4, 134.6, 134.0, 133.7, 131.77, 131.75, 129.2, 127.7, 127.5, 127.3, 126.4, 125.7, 125.6, 125.5, 120.8, 120.3, 120.2, 119.9. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{17}\text{Br}_2\text{N}_2\text{O}_3$: 550.9606; found: 550.9600. FT-IR (neat, cm^{-1}) ν 3349, 2924, 1741, 1685, 1530, 1497, 1118, 756.







Co-1d was obtained as a red oil. $R_f = 0.50$ (EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.90 (s, 1H), 7.87–7.82 (m, 1H), 7.77 (d, $J = 7.6$ Hz, 1H), 7.58–7.51 (m, 2H), 7.41 (t, $J = 7.2$ Hz, 1H), 7.33–7.17 (m, 1H), 7.04–6.89 (m, 2H), 1.93–1.64 (m, 6H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3) δ 192.1, 169.6, 154.3, 150.1, 141.5, 139.8, 137.1, 134.1, 131.7, 127.7, 126.4, 125.9, 125.5, 124.9, 124.7, 124.2, 23.8, 18.2. HRMS (ESI): m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{16}\text{CoN}_2\text{O}_3$: 379.0493; found: 379.0487. FT-IR (neat, cm^{-1}) ν 3048, 2923, 1634, 1606, 1475, 1398, 796, 773.



8. Copies of ^1H , ^{13}C and ^{19}F NMR spectra of silver carboxylates **2a-1**–**2d-16**



















































































































--61.108







2b-16



376 MHz, DMSO-*d*6





















8.525
8.523
8.449
8.447

2.509
2.505
2.500
2.495
2.491




2b-23

400 MHz, DMSO-*d*₆




163.086
152.675
143.500
136.301



40.417
40.210
40.001
39.791
39.583







2b-23



100 MHz, DMSO-*d*₆

















8.551
 8.091
 8.087
 8.070
 8.066
 8.043
 8.025
 8.021
 7.949
 7.946
 7.927
 7.915
 7.893
 7.587
 7.583
 7.570
 7.566
 7.555
 7.551
 7.546
 7.536
 7.532
 7.519
 7.515
 3.351
 2.509
 2.505
 2.500
 2.495
 2.491




2b-29

400 MHz, DMSO-*d*₆






170.451
 134.462
 134.269
 132.897
 130.037
 129.362
 127.939
 127.635
 127.477
 127.285
 126.602
 40.417
 40.209
 40.000
 39.791
 39.582



2b-29

100 MHz, DMSO-*d*₆







8.942
8.935
8.918
7.953
7.949
7.935
7.931
7.925
7.911
7.904
7.891
7.875
7.859
7.843
7.827
7.811
7.795
7.779
7.763
7.747
7.731
7.715
7.699
7.683
7.667
7.651
7.635
7.619
7.603
7.587
7.571
7.555
7.539
7.523
7.507
7.491
7.475

3.338

2.509
2.500
2.491




2b-31
400 MHz, DMSO-*d*6




172.702



136.932
133.870
131.232
129.688
128.441
127.768
127.732
126.326
125.917
125.457



40.626
40.418
40.210
40.001
39.792
39.584
39.374







2b-31
100 MHz, DMSO-*d*6





























--61.912







376 MHz, Pyridine-*d*5



























— 67.231












- 9.066
 - 8.720
 - 8.259
 - 7.592
 - 7.219
 - 7.136
 - 6.083
 - 5.104
 - 4.047
 - 4.032
 - 1.151
 - 1.137
 - 1.118




3d-10
400 MHz, Pyridine-*d*5







- 175.209
 - 170.840
 - 151.965
 - 150.028
 - 149.759
 - 149.489
 - 146.692
 - 145.727
 - 136.320
 - 135.751
 - 135.504
 - 135.257
 - 125.169
 - 123.688
 - 123.440
 - 123.192
 - 104.513
 - 102.513
 - 95.786
 - 48.524
 - 14.265







3d-10
100 MHz, Pyridine-*d*5





























9. Copies of ^1H , ^{13}C and ^{19}F NMR spectra of products **3aa-1–3wa**





















































































— -63.229







3ab-16
376 MHz, CDCl₃















































-62.853



















--68.788

































--64.785

























































-60.585







5
376 MHz, CDCl₃




















10. Failure examples of C–H bond acyloxylation.



11. References

- 1 (a) J.-Y. Lan, H.-S. Xie, X.-X. Lu, Y.-F. Deng, H.-F. Jiang, W. Zeng, *Org. Lett.* **2017**, *19*, 4279; (b) J. Ying, L.-Y. Fu, G.-Q. Zhong, X.-F. Wu, *Org. Lett.* **2019**, *21*, 5694; (c) Y. Yao, Q. Lin, W. Yang, W. Yang, F. Gu, W. Guo, D. Yang, *Chem. Eur. J.* **2020**, *26*, 5607.
- 2 K. J. Alexander, M. McConville, K. R. Williams, K. V. Luzyanin, I. A. O'Neil, R. Cosstick, *Chem. Eur. J.* **2018**, *24*, 3013.
- 3 L. Grigorjeva, O. Daugulis, *Angew. Chem. Int. Ed.* **2014**, *53*, 10209.
- 4 L. Wang, C. W. Barth, M. Sibrian-Vazquez, J. O. Escobedo, M. Lowry, J. Muschler, H. Li, S. L. Gibbs, R. M. Strongin, *ACS Omega* **2017**, *2*, 154.